<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Naproxen: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Naproxen: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Naproxen: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11801" href="/d/html/11801.html" rel="external">see "Naproxen: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12630" href="/d/html/12630.html" rel="external">see "Naproxen: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709165"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious cardiovascular thrombotic events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI), and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>
<p style="text-indent:-2em;margin-left:2em;">Naproxen is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serious gastrointestinal bleeding, ulceration, and perforation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F199854"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aleve [OTC];</li>
<li>All Day Pain Relief [OTC] [DSC];</li>
<li>All Day Relief [OTC];</li>
<li>Anaprox DS;</li>
<li>EC-Naprosyn;</li>
<li>EC-Naproxen;</li>
<li>FT All Day Pain Relief [OTC];</li>
<li>FT Naproxen Sodium [OTC];</li>
<li>GoodSense Naproxen Sodium [OTC];</li>
<li>Mediproxen [OTC];</li>
<li>Naprelan;</li>
<li>Naprosyn</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867643"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Anaprox;</li>
<li>Anaprox DS;</li>
<li>APO-Napro-Na;</li>
<li>APO-Naproxen;</li>
<li>APO-Naproxen EC;</li>
<li>Naprosyn;</li>
<li>Naproxen-250;</li>
<li>Naproxen-500;</li>
<li>Naproxen-Na;</li>
<li>Naxen EC;</li>
<li>Pediapharm Naproxen;</li>
<li>PMS-Naproxen EC [DSC];</li>
<li>PMS-Naproxen [DSC];</li>
<li>PRO-Naproxen EC;</li>
<li>TEVA-Naproxen;</li>
<li>TEVA-Naproxen EC;</li>
<li>TEVA-Naproxen Sodium;</li>
<li>TEVA-Naproxen Sodium DS</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F199906"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Analgesic, Nonopioid;</li>
<li>
                        Nonsteroidal Anti-inflammatory Drug (NSAID), Oral</li></ul></div>
<div class="block doa drugH1Div" id="F199859"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Avoid or use with caution in patients at risk for or with existing cardiovascular disease, GI disease, kidney impairment, chronic liver disease, or a bleeding diathesis. Consider proton pump inhibitor coadministration in patients at risk for GI bleeding (eg, taking dual antiplatelet therapy or an anticoagulant, ≥60 years of age, high doses) (ACCF/ACG/AHA [Abraham 2010]; ACCF/ACG/AHA [Bhatt 2008a]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Use the lowest effective dose for the shortest duration of time. Naproxen is available as naproxen base and sodium salt. All doses in this monograph are expressed as base; 200 mg naproxen base is equivalent to 220 mg naproxen sodium.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> For relief of acute pain, naproxen sodium formulations may be preferred due to more rapid onset.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0aa64061-6e3a-4e32-801e-0989bd1fbc53">Abnormal uterine bleeding, nonacute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding, nonacute (alternative agent) (off-label use): Note: </b>Not indicated for management of acute abnormal bleeding (ie, excessively heavy or prolonged bleeding that requires urgent evaluation). Alternative agent for patients who cannot or choose not to use hormonal therapies (Kaunitz 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>
<i>Immediate release: </i>500 mg at the first sign of menses; may repeat 500 mg 3 to 5 hours later, followed by 250 to 500 mg twice daily for 2 to 3 days or until cessation of bleeding; maximum dose: 1 <b>g</b>/day (Bofill Rodriguez 2019; Fraser 1991; Kaunitz 2022; Lethaby 2019; Rybo 1981; Ylikorkala 1986).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="462a3a59-e36e-4308-9661-36c83a515c19">Anti-inflammatory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory (eg, for arthritis associated with rheumatic disease): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release</i>: 250 to 500 mg every 12 hours; maximum dose: 1.5 g/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i> 750 mg to 1 g once daily; maximum dose: 1.5 g/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Some experts generally recommend a maximum dose of 1 g/day for chronic use, except during a disease flare when 1.25 to 1.5 g/day may be considered for several weeks until flare resolves (Solomon 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e869268c-ef62-438f-96df-0870b699a85a">Dysmenorrhea, primary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysmenorrhea, primary: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i> Initial: 500 mg once, begin at menses onset or 1 to 2 days prior to onset of menses for severe symptoms; then 500 mg every 12 hours as needed or 250 mg every 6 to 8 hours as needed; maximum dose: 1.25 g/day on day 1, then 1 g/day thereafter; usual duration: 1 to 5 days (Bofill Rodriguez 2019; Smith 2020; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i> Initial: 1 g once daily as needed; begin at menses onset or 1 to 2 days prior to onset of menses for severe symptoms; may increase to a maximum of 1.5 g once daily if needed; usual duration: 1 to 5 days (Bofill Rodriguez 2019; Smith 2020; manufacturer’s labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="329ed298-f3e6-444f-90c2-4d78bdfdcf71">Fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fever (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>
<i>OTC labeling (patient-guided therapy): Immediate release: </i>Initial: 200 to 400 mg once, followed by 200 mg every 8 to 12 hours as needed; maximum dose: 400 mg in any 8- to 12-hour period or 600 mg in a 24-hour period.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6e76d75-22ca-4f0b-a2dd-704b9135d6b7">Gout, prophylaxis during initiation of urate-lowering therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, prophylaxis during initiation of urate-lowering therapy (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients not able to tolerate or with contraindications to colchicine (ACR [FitzGerald 2020]; EULAR [Richette 2017]; Perez-Ruiz 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b>
<i>Immediate release:</i> 250 mg twice daily (ACR [FitzGerald 2020]; EULAR [Richette 2017]; Perez-Ruiz 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of prophylaxis: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Patients without tophi: ≥3 to 6 months after initiating urate-lowering therapy (ACR [FitzGerald 2020]; EULAR [Richette 2017]; Perez-Ruiz 2020).</p>
<p style="text-indent:-2em;margin-left:8em;">Patients with ≥1 tophi: Optimal duration is uncertain; some experts continue prophylaxis ≥6 months; some patients with severe disease may require &gt;12 months prophylaxis (Perez-Ruiz 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a81184b-235e-4be1-8cc9-23a33b10cc65">Gout, treatment, acute flares</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, treatment, acute flares:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release: </i>Initial: 500 mg twice daily within 24 to 48 hours of flare onset; reduce dose as symptoms improve. Discontinue a few days after resolution of clinical signs (usual total duration: 5 to 7 days); longer duration may be required if therapy is delayed (ACR [FitzGerald 2020]; Gaffo 2023; Janssens 2008; Roddy 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i> Initial: 1 to 1.5 g once on day 1, followed by 1 g once daily starting on day 2; initiate within 24 to 48 hours of flare onset; reduce dose as symptoms improve. Discontinue a few days after resolution of clinical signs (usual total duration: 5 to 7 days); longer duration may be required if therapy is delayed (ACR [FitzGerald 2020]; Gaffo 2023; manufacturer’s labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94e2a3ee-a6a7-47a4-9a9e-1102ebb9cf5e">Migraine, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, acute treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use as monotherapy in mild to moderate attacks not associated with vomiting or severe nausea; may be used in combination with triptans for severe migraine (CHS [Worthington 2013]; Schwedt 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b>
<i>Immediate release:</i> 500 to 750 mg once (CHS [Worthington 2013]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="10e80117-63f7-43fa-95c9-0c85ee3d6a40">Pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain (monotherapy or as adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i> Initial: 500 mg once, followed by 250 to 500 mg every 12 hours as needed<b> or</b> 250 mg every 6 to 8 hours as needed; maximum dose: 1.25 g on day 1, then 1 g/day thereafter. For postoperative pain, doses may be scheduled initially (Schwenk 2020, manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i> 1 g once daily; may increase to 1.5 g once daily for acute pain, then reduce to a usual maximum dose of 1 g/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>OTC labeling (patient-guided therapy): Immediate release:</i> Initial: 200 to 400 mg once, followed by 200 mg every 8 to 12 hours as needed; maximum dose: 400 mg in any 8- to 12-hour period or 600 mg in a 24-hour period.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991053"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary (&lt;1% of unchanged drug excreted in the urine) (Anttila 1980; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 to &lt;60 mL/minute: No dosage adjustment necessary (&lt;1% of unchanged drug excreted in the urine) (Anttila 1980; expert opinion). However, use the lowest effective dose for the shortest duration possible. Use of analgesics other than nonsteroidal anti-inflammatory drugs (NSAIDs) or topical NSAIDs may be preferred. Avoid use in patients at high risk for acute kidney injury (ie, volume depleted, hypotensive, elderly, or taking concurrent nephrotoxic medications) (Baker 2020; KDIGO 2013; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤30 mL/minute: Avoid use due to increased risk of acute kidney injury (KDIGO 2013); use of analgesics other than NSAIDs or topical NSAIDs are preferred. However, in select patients where alternatives are not effective, after careful assessment of risks versus benefits, use of naproxen may be considered; use the lowest effective dose for the shortest duration possible with close monitoring of kidney function (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (Davies 1997): Avoid use, as patients with end-stage kidney disease may be at increased risk for bleeding (eg, GI), cardiovascular adverse effects, and loss of residual kidney function (Kurella 2003; expert opinion). However, in select patients after careful assessment of risks versus benefits, use of naproxen may be considered; use the lowest effective dose for the shortest duration possible (Koncicki 2017; expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (high protein binding): Avoid use, as patients with end-stage kidney disease may be at increased risk for bleeding (eg, GI), cardiovascular adverse effects, and loss of residual kidney function (Kurella 2003; expert opinion). However, in select patients after careful assessment of risks versus benefits, use of naproxen may be considered; use the lowest effective dose for the shortest duration possible (Koncicki 2017; expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Avoid use (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Avoid use (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute kidney injury while on naproxen therapy:</b> Discontinue use (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988289"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer’s labeling; use with caution to avoid adverse effects and discontinue if hepatic function worsens.</p></div>
<div class="block doe drugH1Div" id="F199860"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Unless alternative agents are ineffective and a gastroprotective agent can be administered, avoid short-term scheduled use in combination with corticosteroids, anticoagulants, or antiplatelet agents or chronic use with or without medications that increase risk for bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>). Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F199881"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12630" href="/d/html/12630.html" rel="external">see "Naproxen: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing</b>: Dosage expressed as naproxen base; 200 mg naproxen base is equivalent to 220 mg naproxen sodium. In pediatric patients, all dosing is for either the immediate-release or controlled-/delayed-release preparations; however, delayed- or controlled-released dosage forms may not be appropriate for use in smaller pediatric patients (eg, calculated dose is less than available dosage forms, patient unable to swallow solid dosage form).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="83a06dc0-cd8b-47fb-9f5f-17e0f0599535">Analgesia/pain, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesia/pain, mild to moderate:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents &lt;60 kg: Limited data available: Oral: 5 to 7 mg/kg/dose every 8 to 12 hours; maximum daily dose: 1,000 mg/<b>day</b> (Berde 2002; Zeltzer 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents ≥60 kg: Limited data available: Oral: 5 to 7 mg/kg/dose every 8 to 12 hours; maximum daily dose: 1,000 mg/<b>day</b> (Berde 2002; Zeltzer 2020). <b>Note:</b> Usual adult dose is 500 mg once, followed by 250 to 500 mg every 12 hours as needed<b> or</b> 250 mg every 6 to 8 hours as needed (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>OTC labeling</i>: Children ≥12 years and Adolescents: Immediate release (eg, Aleve): Oral: 200 mg every 8 to 12 hours; if needed may use 400 mg for the initial dose; maximum daily dose: 600 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62637659-f98d-4a3f-aec5-dbd1f84dc2b2">Ankylosing spondylitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ankylosing spondylitis:</b> Limited data available: Children and Adolescents: Immediate release, controlled/delayed release: Oral: 15 to 20 mg/kg/<b>day</b> in 2 divided doses; maximum daily dose: 1,500 mg/<b>day</b>; adult dosing suggests limiting this maximum daily dose to &lt;6 months of therapy (APS 2016; Weiss 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="329ed298-f3e6-444f-90c2-4d78bdfdcf71">Fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fever: </b>
<i>OTC labeling:</i> Children ≥12 years and Adolescents: Immediate release (eg, Aleve): Oral: 200 mg every 8 to 12 hours; if needed may use 400 mg for the initial dose; maximum daily dose: 600 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis (JIA):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Scheduled nonsteroidal anti-inflammatory drug (NSAID) therapy may be an appropriate first-line treatment option with or without intraarticular glucocorticoids for certain types of JIA; however, due to adverse effect risks with NSAIDs, therapy should be discontinued if not found beneficial after an adequate trial (ACR [Onel 2022]; ACR [Ringold 2019]). An adequate NSAID trial duration has not been defined in expert recommendations (ACR [Onel 2022]); in clinical trials of NSAIDs for JIA, initial beneficial effects were generally observed within 2 weeks (Ruperto 2005). As initial therapy for polyarticular JIA, NSAID monotherapy should be not initiated over a disease-modifying anti-rheumatic drug (ACR [Ringold 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Immediate release, controlled/delayed release: Oral: 10 to 15 mg/kg/<b>day</b> in 2 divided doses; maximum daily dose: 1,000 mg/<b>day</b> (Hollingworth 1993; Litalien 2001; Ruperto 2005; Shi 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54d9d4aa-eb0f-4f32-a8ca-66e6199c3058">Migraine, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, treatment:</b> Limited data available: Children &gt;6 years and Adolescents: Immediate release, controlled/delayed release: Oral: 5 to 7 mg/kg/dose every 8 to 12 hours; maximum daily dose: 1,000 mg/<b>day</b>; dosing based on usual analgesic dosing for naproxen and migraine occurrence (Berde 2002; Géraud 2004; Gunner 2008; Zeltzer 2020). <b>Note:</b> In pediatric patients ≥12 years of age, improved efficacy has been shown using a fixed-dose combination with sumatriptan (Derosier 2012; McDonald 2011; Winner 2015); refer to Sumatriptan and Naproxen monograph for additional information.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130666"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: There are no specific dosage adjustments provided in the manufacturer's labeling; use with caution and consider using a reduced dose. KDIGO guidelines recommend to temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury (KDIGO 2013; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p></div>
<div class="block dohp drugH1Div" id="F51130667"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer’s labeling; use with caution and consider using a reduced dose.</p></div>
<div class="block arsc drugH1Div" id="F56437629"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of serious adverse cardiovascular (CV) events, including <b>acute myocardial infarction</b> (MI), <b>cerebrovascular accident</b>, and CV death. New-onset <b>hypertension</b> or <b>exacerbation of hypertension</b> may occur with NSAID use which may also contribute to an increased risk of CV events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29020251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29020251'])">Ref</a></span>). New-onset or exacerbation of <b>heart failure</b> may also occur with cyclooxygenase (COX)-2 selective NSAIDs (ie, coxibs) and nonselective NSAIDs, including ibuprofen, resulting in an increased risk of hospitalizations for heart failure and death in patients with heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23741058','lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23741058','lexi-content-ref-FDA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Data collected by the Coxib and traditional NSAID Trialists’ (CNT) Collaborative has shown that high-dose naproxen (1,000 mg daily) may have the most favorable CV risk profile among NSAIDs analyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390'])">Ref</a></span>); however, data from the PRECISION trial showed no difference with regards to risk between naproxen, ibuprofen, or celecoxib after a treatment duration of therapy of ~3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959716'])">Ref</a></span>). Additional trials are also conflicted with regards to the risk of CV events with naproxen as compared to other NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15705456','lexi-content-ref-18541831','lexi-content-ref-15947398','lexi-content-ref-21224324','lexi-content-ref-12020179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15705456','lexi-content-ref-18541831','lexi-content-ref-15947398','lexi-content-ref-21224324','lexi-content-ref-12020179'])">Ref</a></span>). The FDA states that there is insufficient data to determine if risk of myocardial infarction or stroke is definitely higher or lower for any particular NSAID as compared to another (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; inhibition of COX-2 by NSAIDs results in a reduction in the production of prostaglandin I<sub>2</sub> (prostacyclin) in the vascular endothelium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11509629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11509629'])">Ref</a></span>); animal studies have shown that reduced prostacyclin activity may result in a predisposition to vascular injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11964481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11964481'])">Ref</a></span>). In addition, prostaglandins inhibit sodium resorption in the thick ascending loop of Henle and collecting tubule; therefore, a reduction in prostaglandin synthesis by NSAIDs may cause sodium and fluid retention and result in hypertension and decreased efficacy of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23741058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23741058'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; increased risk may be apparent within the first weeks following initiation of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2','lexi-content-ref-21555710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2','lexi-content-ref-21555710'])">Ref</a></span>); longer duration of therapy may further increase risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• ≥65 years of age</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (especially with regards to CV thrombotic risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use and frequent use (eg, ≥22 days per month) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16534006','lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16534006','lexi-content-ref-FDA.2'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiovascular disease (CVD) or presence of risk factors for CVD, including use following coronary artery bypass graft surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24280110','lexi-content-ref-27959716','lexi-content-ref-20031832','lexi-content-ref-21555710','lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24280110','lexi-content-ref-27959716','lexi-content-ref-20031832','lexi-content-ref-21555710','lexi-content-ref-25710657'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note: </b>Relative risk appears to be similar in those with and without known CVD or risk factors for CVD; however, absolute incidence of serious CV thrombotic events appears to be higher in patients with known CVD or risk factors for CVD due to an increased baseline risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs), especially nonselective NSAIDs such as naproxen, is associated with an increased risk of serious gastrointestinal (GI) adverse events, including <b>gastrointestinal inflammation</b>, <b>gastrointestinal hemorrhage</b>, <b>gastrointestinal ulcer</b>, and <b>gastrointestinal</b>
<b>perforation</b>; severity may range from asymptomatic to fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390','lexi-content-ref-28756267','lexi-content-ref-31937550','lexi-content-ref-9494148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390','lexi-content-ref-28756267','lexi-content-ref-31937550','lexi-content-ref-9494148'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; inhibition of cyclooxygenase (COX)-1 by NSAIDs results in a reduction in the production of mucosal-protective prostaglandin E<sub>2 </sub>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9626023','lexi-content-ref-10377455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9626023','lexi-content-ref-10377455'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; GI events can occur at any time during use and without warning symptoms. A longer duration of use (eg, ≥7 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33238721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33238721'])">Ref</a></span>) is associated with a greater risk.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Longer duration of use (eg, ≥7 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33238721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33238721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7909103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7909103'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Prior history of peptic ulcer disease and/or GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Concomitant use of agents known to increase the risk of GI bleeding (eg, aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>), anticoagulants, corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443','lexi-content-ref-2012355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443','lexi-content-ref-2012355'])">Ref</a></span>), selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Comorbid <i>Helicobacter pylori </i>infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16469671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16469671'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Advanced liver disease/cirrhosis</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Coagulopathy</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Smoking</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Consumption of alcohol</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>People with poor general health status</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Small intestine damage: Small intestine bacterial overgrowth (SIBO), including SIBO induced by proton pump inhibitor therapy, may be associated with an increased risk of small intestine damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28052268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28052268'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs), including naproxen, is associated with <b>prolonged bleeding time</b> and an increased risk for <b>hemorrhage</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15037526','lexi-content-ref-18359332','lexi-content-ref-25402512','lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15037526','lexi-content-ref-18359332','lexi-content-ref-25402512','lexi-content-ref-25710657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">In addition, drug-induced <b>hemolytic anemia</b> may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25247621','lexi-content-ref-3545733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25247621','lexi-content-ref-3545733'])">Ref</a></span>). Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, <b>agranulocytosis</b>, <b>aplastic anemia</b>, <b>neutropenia</b>, <b>thrombocytopenia</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33100559','lexi-content-ref-8379803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33100559','lexi-content-ref-8379803'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Prolonged bleeding time: Inhibition of cyclooxygenase (COX)-1 by nonselective NSAIDs causes a decrease in the production of prostaglandins, prostacyclins, and thromboxanes, including thromboxane A<sub>2</sub> (TxA<sub>2</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2724096']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2724096'])">Ref</a></span>). As a result, patients may exhibit a decrease in platelet adhesion and aggregation and subsequent prolonged bleeding time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29891025','lexi-content-ref-18193919','lexi-content-ref-19269020','lexi-content-ref-1321554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29891025','lexi-content-ref-18193919','lexi-content-ref-19269020','lexi-content-ref-1321554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Blood dyscrasias: Not clearly established; anemia may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Prolonged bleeding time: Rapid; suppression of platelet COX-1 activity occurs within hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15037526','lexi-content-ref-18359332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15037526','lexi-content-ref-18359332'])">Ref</a></span>). In patients receiving antithrombotic therapy after myocardial infarction, the use of NSAIDs has been associated with an increased risk of bleeding and excess thrombotic events even after short-term treatment (eg, &lt;3 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25710657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Bleeding events:</p>
<p style="text-indent:-2em;margin-left:8em;">- Preexisting coagulation disorders</p>
<p style="text-indent:-2em;margin-left:8em;">- Concomitant use of agents known to increase the risk of bleeding (eg, anticoagulants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15668365','lexi-content-ref-24733305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15668365','lexi-content-ref-24733305'])">Ref</a></span>), antithrombotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25710657'])">Ref</a></span>), antiplatelet agents [eg, aspirin], selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>), or serotonin norepinephrine reuptake inhibitors)</p>
<p style="text-indent:-2em;margin-left:8em;">- Use during and immediately following surgical procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15809462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15809462'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal anti-inflammatory drugs (NSAIDs), including naproxen, may cause mild transaminase elevations, especially with higher doses. Rarely, acute hepatitis may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3115366','lexi-content-ref-17715646','lexi-content-ref-26991794','lexi-content-ref-30112779','lexi-content-ref-1608854','lexi-content-ref-7443602']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3115366','lexi-content-ref-17715646','lexi-content-ref-26991794','lexi-content-ref-30112779','lexi-content-ref-1608854','lexi-content-ref-7443602'])">Ref</a></span>). Severe liver injury requiring liver transplantation has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23325533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23325533'])">Ref</a></span>). Most cases of liver injury are likely reversible with rapid recovery following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1608854','lexi-content-ref-7443602']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1608854','lexi-content-ref-7443602'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; dose-related. Proposed mechanisms include a toxic metabolite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17715646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17715646'])">Ref</a></span>) or a hypersensitivity reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7443602']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7443602'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; onset of NSAID-induced hepatotoxicity is generally classified as moderate (30 to 90 days) to long (&gt;90 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929376'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior NSAID-related liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3115366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3115366'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note: </b>Cross-reactivity may occur among propionic acid derivatives (eg, ibuprofen, naproxen, ketoprofen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3115366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3115366'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity reactions (immediate and delayed) involving the skin (eg, <b>angioedema</b>, <b>urticaria</b>), airways (eg, <b>dyspnea</b>, rhinorrhea) and/or other organs have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Clinical phenotypes of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity reactions include NSAID-exacerbated respiratory disease (NERD), NSAID-induced urticaria/angioedema (NIUA), NSAID-exacerbated cutaneous disease (NECD) and single NSAID-induced urticaria/angioedema or anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26841325','lexi-content-ref-31545385','lexi-content-ref-15647052','lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26841325','lexi-content-ref-31545385','lexi-content-ref-15647052','lexi-content-ref-24117484'])">Ref</a></span>). Delayed hypersensitivity reactions including <b>drug rash with eosinophilia and systemic symptoms </b>(DRESS) and <b>Stevens-Johnson syndrome </b>(SJS) have also been associated with naproxen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sasi.2020','lexi-content-ref-20101062']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sasi.2020','lexi-content-ref-20101062'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate reactions: Non–dose-related; most reactions (ie, NERD, NECD, NIUA) are non-immunologic related to inhibition of cyclooxygenase-1 (COX-1) with subsequent activation of mast cells and eosinophils causing release of inflammatory mediators including cysteinyl-leukotrienes (cysLTs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Some immediate reactions are IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26841325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26841325'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed reactions: Delayed hypersensitivity reactions are T-cell–mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-25749768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-25749768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate reactions: Rapid; occur within 1 hour of administration but may occur several hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed reactions (including DRESS and SJS): Varied; generally occurs after 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-31264694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-31264694'])">Ref</a></span>), although some patients may develop symptoms within 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28488978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28488978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of chronic rhinosinusitis with nasal polyps, family history of NERD and/or severe asthma may increase the risk of NERD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30216468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30216468'])">Ref</a></span>). The prevalence of NERD in adult patients with asthma is ~10% to 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30216468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30216468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic urticaria increases the risk of NECD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). NSAID-induced reactions are less frequent and less intense when chronic urticaria is in remission or under control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25749768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25749768'])">Ref</a></span>). Approximately 12% to 30% of patients with chronic idiopathic urticaria develop exacerbations of their disease with use of naproxen and other COX-1 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28483309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28483309'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between aspirin and NSAIDs, including naproxen (with predominant COX-1 inhibition) have been described in patients with a history of NERD, NECD and NIUA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Cross-reactivity between aspirin/NSAID and acetaminophen, a weak COX inhibitor and between aspirin/NSAID and nonselective COX-2 inhibitors (eg, meloxicam, nimesulide) may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21834936','lexi-content-ref-24587953','lexi-content-ref-17609236']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21834936','lexi-content-ref-24587953','lexi-content-ref-17609236'])">Ref</a></span>). Although selective COX-2 inhibitors (eg, celecoxib, etoricoxib) are generally tolerated in patients with NERD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21631520','lexi-content-ref-30207919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21631520','lexi-content-ref-30207919'])">Ref</a></span>), cross-reactions may occur especially in patients with histories of urticaria/angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21834936','lexi-content-ref-24587953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21834936','lexi-content-ref-24587953'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity may occur among propionic acid derivatives (eg, ibuprofen, naproxen, ketoprofen) in patients with histories of immediate hypersensitivity reactions to naproxen, but tolerance to aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26841325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26841325'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Kidney effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs), including naproxen, is associated with an increased risk of several kidney-specific effects: <b>Hemodynamically-mediated</b>
<b>acute kidney injury</b>, <b>interstitial nephritis</b> (with or without <b>nephrotic syndrome</b>), and <b>renal papillary necrosis</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodynamically-mediated acute kidney injury (AKI): Hemodynamically-mediated AKI may occur following use of either cyclooxygenase (COX)-2 selective NSAIDs (ie, coxibs) or nonselective NSAIDs, including naproxen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922','lexi-content-ref-25439535','lexi-content-ref-17005625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922','lexi-content-ref-25439535','lexi-content-ref-17005625'])">Ref</a></span>); the risk may be greater with nonselective NSAIDs, especially indomethacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16813969','lexi-content-ref-26945352','lexi-content-ref-12014386','lexi-content-ref-23633310','lexi-content-ref-10974130','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16813969','lexi-content-ref-26945352','lexi-content-ref-12014386','lexi-content-ref-23633310','lexi-content-ref-10974130','lexi-content-ref-10390124'])">Ref</a></span>). The risk of developing AKI is decreased upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15754275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15754275'])">Ref</a></span>). In patients who develop AKI, kidney function is likely to return to baseline following prompt discontinuation of the offending NSAID and supportive care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>); however, the mechanism of the damage and other concurrent factors can contribute to irreversibility.</p>
<p style="text-indent:-2em;margin-left:4em;">Acute interstitial nephritis (AIN) with or without nephrotic syndrome: Patients may develop NSAID-associated proteinuria combined with interstitial nephritis and varying degrees of kidney impairment; the “classic triad” of fever, rash, and eosinophilia is less commonly observed in NSAID-associated AIN than with antibiotic-induced AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6363936','lexi-content-ref-31416889','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6363936','lexi-content-ref-31416889','lexi-content-ref-10390124'])">Ref</a></span>). Kidney histology may reveal minimal change glomerulonephritis or membranous nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-31416889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-31416889'])">Ref</a></span>). While use of naproxen has been associated with this clinical picture; the risk may be greatest with fenoprofen as compared to other NSAIDS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-10390124'])">Ref</a></span>). Proteinuria generally improves within weeks following discontinuation; full recovery may require treatment and take up to a year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31416889','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31416889','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Papillary necrosis: Chronic use of NSAIDs, including naproxen, has resulted in the development of papillary necrosis which may occur in conjunction with chronic interstitial nephritis and progressive decline in glomerular filtration rate as a clinical syndrome known as analgesic nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12512867','lexi-content-ref-7306246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12512867','lexi-content-ref-7306246'])">Ref</a></span>). However, controversy exists on the degree to which NSAID use increases the risk for chronic kidney disease and analgesic nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17410098','lexi-content-ref-32317121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17410098','lexi-content-ref-32317121'])">Ref</a></span>). Acute papillary necrosis may occur following NSAID overdose, especially in a setting of severe dehydration or intravascular volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21705120','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21705120','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodynamically-mediated AKI: Dose- and time-related; inhibition of cyclooxygenase (COX)-1 and COX-2 by NSAIDs results in a reduced production of nephroprotective prostaglandins and subsequent attenuation of renal vasodilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3045551','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3045551','lexi-content-ref-10390124'])">Ref</a></span>). In addition, an increase in vasoconstriction of the afferent arteriole and impaired renal blood flow causes a reduction in the glomerular capillary pressure and filtration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25439535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25439535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">AIN with or without nephrotic syndrome: Not clearly established. Following inhibition of COX-1 and COX-2 by NSAIDs, arachidonic acid is formed which may be further metabolized to leukotrienes via the lipoxygenase pathway; leukotrienes may increase vascular permeability within glomerular capillaries and peritubular capillaries and increase lymphocyte recruitment and activation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Papillary necrosis: Time-related; exact mechanism is not clearly established; may be due to direct toxicity and/or inhibition of prostaglandin-mediated vasodilation resulting in ischemic necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25439535','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25439535','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">AKI: Rapid; may occur within days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2183665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2183665'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">AIN with or without nephrotic syndrome: Varied; mean time of onset of ~5 months (range: 2 weeks to 18 months) has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:8em;">• AKI:</p>
<p style="text-indent:-2em;margin-left:10em;">- Preexisting kidney impairment</p>
<p style="text-indent:-2em;margin-left:10em;">- Chronic kidney disease</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>• Note:</b> High cumulative doses (eg, ibuprofen &gt;300 mg/day) may increase the risk for progression of chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17349452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17349452'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31264694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31264694'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">• <b>Note: </b>NSAID-associated AKI may also occur in pediatric patients, even at therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23453549','lexi-content-ref-23360563']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23453549','lexi-content-ref-23360563'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hemodynamically-mediated AKI:</p>
<p style="text-indent:-2em;margin-left:10em;">- Preexisting conditions which result in decreased effective arterial circulation (ie, conditions where renal blood flow/renal perfusion may be dependent on prostaglandin-mediated vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:12em;">Volume depletion (eg, due to concomitant diuretic use, nausea, or vomiting)</p>
<p style="text-indent:-2em;margin-left:12em;">Heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15754275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15754275'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">Cirrhosis and ascites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-447795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-447795'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">Nephrotic syndrome</p>
<p style="text-indent:-2em;margin-left:10em;">- Concomitant use of diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or calcineurin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29799625','lexi-content-ref-23299844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29799625','lexi-content-ref-23299844'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• AIN with or without nephrotic syndrome: Prior history of NSAID-induced nephrotic syndrome; recurrence has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10879670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10879670'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Papillary necrosis (acute):</p>
<p style="text-indent:-2em;margin-left:10em;">- Massive NSAID ingestion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Intravascular volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21705120','lexi-content-ref-25439535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21705120','lexi-content-ref-25439535'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Papillary necrosis (chronic)/analgesic nephropathy: Chronic concomitant use of other analgesics (eg, aspirin, acetaminophen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pseudoporphyria</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pseudoporphyria</b> including erythema, skin fragility, blistering, and scarring in sun-exposed skin has been reported in adult and pediatric patients (Howard 1985, Wallace 1994); children with juvenile idiopathic arthritis (JIA) appear to be at an increased risk with a reported incidence of 10% to 12% (De Silva 2000, Lang 1994). Sun-exposed areas of the body are more commonly affected and include the dorsal aspect of the hands, the face, and the extensor surfaces of the legs (Frank 2018, Lang 1994). Time to resolution of the rash in children with JIA is variable (median: 21 days [range: 4 days to 6 weeks]); facial scarring can be disfiguring and may be persistent (DeSilva 2000, Lang 1994).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; hypothesized to be a nonimmune-mediated phototoxic effect resulting in cell membrane damage (Lang 1994). This, although, does not seem to be the only contributing factor, as pseudoporphyria has been reported in climates with low levels of sunshine (De Silva 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; duration of treatment with naproxen and the development of pseudoporphyria is not well reported (Howard 1985, Wallace 1994). One pediatric study included only patients receiving naproxen treatment for ≥4 weeks with a median onset of 11 months (range: 1 month to 18 months) (De Silva 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age &lt;18 years (Lang 1994)</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid JIA (Lang 1994)</p>
<p style="text-indent:-2em;margin-left:6em;">• Fair skin (De Silva 2000)</p>
<p style="text-indent:-2em;margin-left:6em;">• Blue/gray eyes (De Silva 2000)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ultraviolet A (UVA) exposure (eg sun exposure, tanning bed use) (Frank 2018, De Silva 2000)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F199822"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (≤14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (3% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (&lt;3%), edema (≤9%), hypertension (&lt;3%; including exacerbation of hypertension), palpitations (&lt;3%), peripheral edema (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (&lt;3%), ecchymoses (≤9%), pruritus (≤9%), skin rash (≤9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (&lt;3%), increased thirst (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3% to 9%), constipation (3% to 9%), diarrhea (≤9%), dysphagia (&lt;3%), flatulence (&lt;3%), gastritis (&lt;3%), gastrointestinal hemorrhage, gastrointestinal perforation, gastrointestinal ulcer (including gastric ulcer and esophageal ulcer), heartburn (3% to 9%), nausea (3% to 9%), stomatitis (&lt;3%; including oral mucosal ulcer), vomiting (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (&lt;3%), urinary tract infection (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&lt;3%), purpuric disease (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (≤9%), drowsiness (3% to 9%), insomnia (&lt;3%), pain (3% to 9%), paresthesia (&lt;3%), vertigo (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;3%), arthropathy (&lt;3%), asthenia (&lt;3%), back pain (3% to 9%), lower limb cramp (&lt;3%), myalgia (&lt;3%), tendinopathy (&lt;3%; including fibrotendinitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory disturbance (&lt;3%; including auditory impairment and deafness), tinnitus (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (&lt;3%), dyspnea (≤9%), flu-like symptoms (10%), increased cough (&lt;3%), pharyngitis (3% to 9%), rhinitis (3% to 9%), sinusitis (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, aortic valve stenosis, bundle branch block, cardiac arrhythmia, coronary artery disease, deep vein thrombosis, ECG abnormality, heart failure, right heart failure, subdural hematoma, syncope, tachycardia, vasculitis, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, alopecia, bullous skin disease, cellulitis, contact dermatitis, dermal ulcer, eczema, epidermolysis bullosa, erythema multiforme, erythema nodosum, herpes simplex dermatitis, lichen planus, nail disease, photodermatitis, pustular rash, skin necrosis, skin photosensitivity, Stevens-Johnson syndrome, subcutaneous nodule, toxic epidermal necrolysis, urticaria, vasculitis of the skin, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, alkalosis, decreased glucose tolerance, dehydration, glycosuria, hypercholesteremia, hyperkalemia, hyperuricemia, hypoglycemia, hypokalemia, menstrual disease, porphyria cutanea tarda, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, anorexia, aphthous stomatitis, cholecystitis, cholelithiasis, colitis, eructation, esophageal achalasia, esophagitis, exacerbation of Crohn disease, exacerbation of ulcerative colitis, gastroenteritis, gastrointestinal candidiasis, gastrointestinal inflammation, gastrointestinal necrosis, gastrointestinal obstruction, hematemesis, melena, mucous membrane abnormality, pancreatitis, periodontal abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea, dysuria, hematuria, infertility, nephrotic syndrome, nocturia, pelvic pain, prostatic disease, pyuria, urinary frequency, urinary incontinence, urinary retention, uterine hemorrhage, uterine spasm, vaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic<b>: </b>Agranulocytosis, aplastic anemia, eosinophilia, granulocytopenia, hemolytic anemia, hemorrhage, neutropenia (Strom 1993), prolonged bleeding time, rectal hemorrhage, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, hepatosplenomegaly, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, fixed drug eruption, hypersensitivity reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess, herpes zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, amnesia, anxiety, aseptic meningitis, ataxia, chills, cognitive dysfunction, confusion, depression, emotional lability, hypertonia, lack of concentration, malaise, migraine, myasthenia, nervousness, neuralgia, neuritis, paralysis, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture, bursitis, Lambert-Eaton syndrome, neck pain, neck stiffness, ostealgia, systemic lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal lacrimation, amblyopia, blepharoptosis, cataract, conjunctivitis, corneal opacity, diplopia, eye pain, keratoconjunctivitis, optic neuritis (including retrobulbar), optic papillitis, papilledema, scleritis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Glomerulonephritis, increased blood urea nitrogen, increased serum creatine, interstitial nephritis, nephrolithiasis, pyelonephritis, renal disease (nephrosclerosis), renal failure syndrome, renal pain, renal papillary necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, eosinophilic pneumonitis, epistaxis, laryngitis, pneumonia, pulmonary edema, respiratory distress</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Coronary thrombosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cerebrovascular accident (FDA 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Pseudoporphyria (Lang 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (idiosyncratic) (Chalasani 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Guerrero Gómez 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Rahman 2014)</p></div>
<div class="block coi drugH1Div" id="F199837"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to naproxen (eg, anaphylactic reactions, serious skin reactions) or any component of the formulation; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; use in the setting of coronary artery bypass graft (CABG) surgery</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Active gastric, duodenal, or peptic ulcers; active GI bleeding; cerebrovascular bleeding or other bleeding disorders; active GI inflammatory disease; severe liver impairment or active liver disease; severe renal impairment (CrCl &lt;30 mL/minute) or deteriorating renal disease; severe uncontrolled heart failure; known hyperkalemia; third trimester of pregnancy; breast-feeding; inflammatory lesions or recent bleeding of the rectum or anus (suppository only); use in patients &lt;16 years of age (suppository only); use in patients &lt;18 years of age (naproxen enteric coated and sustained release tablets and naproxen sodium tablets); use in children &lt;2 years (naproxen tablets and suspension).</p></div>
<div class="block war drugH1Div" id="F199819"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects that may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long-term therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in patients ≥65 years of age, in patients with diabetes or renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe and potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Gastric ulceration: Avoid chronic use of oral nonselective NSAIDs after bariatric surgery; development of anastomotic ulcerations/perforations may occur (Bhangu 2014; Mechanick 2020). Short-term use of celecoxib or IV ketorolac are recommended as part of a multimodal pain management strategy for postoperative pain (Chou 2016a; Horsley 2019; Thorell 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Not for self-medication (OTC use) in children &lt;12 years.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have had recurring stomach pain or upset, ulcers, bleeding problems, asthma, high BP, heart or kidney disease, other serious medical problems, are currently taking a diuretic, anticoagulant, other NSAIDs, or are ≥60 years of age. Do not exceed recommended dosages and duration, due to an increased risk of GI bleeding, MI, and stroke. Patients should stop use and consult a healthcare provider if symptoms get worse, newly appear, or continue; if an allergic reaction occurs; if feeling faint, vomit blood or have bloody/black stools; if having difficulty swallowing or heartburn, or if fever lasts for &gt;3 days or pain &gt;10 days. Consuming ≥3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878559"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Macrophage activation syndrome has been observed in children and adolescents diagnosed with systemic juvenile idiopathic arthritis on daily nonsteroidal anti-inflammatory drug therapy for extended periods of time; causality not established (Sawhney 2001; Stéphan 2001).</p></div>
<div class="block dosfc drugH1Div" id="F23884418"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">EnovaRX-Naproxen and Equipto-Naproxen creams are compounded from a kit.  Refer to manufacturer’s package insert for compounding instructions. </p>
<p style="text-indent:-2em;margin-left:2em;">Naproxen Comfort Pac kit contains naproxen tablets and Duraflex Comfort Gel</p>
<p style="text-indent:-2em;margin-left:2em;">Flanax Pain Relief kit contains naproxen tablets and Flanax Liniment</p></div>
<div class="block foc drugH1Div" id="F199830"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aleve: 220 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Naproxen Sodium: 220 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 220 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naprosyn: 125 mg/5 mL (473 mL) [contains fd&amp;c yellow #6 (sunset yellow), methylparaben, sorbitol; pineapple-orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg/5 mL (473 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naprosyn: 500 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 375 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aleve: 220 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">All Day Pain Relief: 220 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">All Day Relief: 220 mg [gluten free; contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anaprox DS: 550 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT All Day Pain Relief: 220 mg [gluten free; contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Naproxen Sodium: 220 mg [gluten free; contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mediproxen: 220 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 220 mg, 275 mg, 550 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EC-Naprosyn: 375 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EC-Naproxen: 375 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 375 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as sodium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naprelan: 375 mg, 500 mg, 750 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 375 mg, 500 mg, 750 mg</p></div>
<div class="block geq drugH1Div" id="F199815"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F199839"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Aleve Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 mg (per each): $0.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Naproxen Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 mg (per each): $0.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Naprosyn Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per mL): $2.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Naproxen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per mL): $2.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Naprelan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">375 mg (per each): $26.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $23.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $27.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Naproxen Sodium ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">375 mg (per each): $21.42 - $21.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $21.52 - $21.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $24.66 - $26.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (EC-Naprosyn Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">375 mg (per each): $5.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $7.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Naproxen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">375 mg (per each): $1.06 - $6.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $1.30 - $8.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Aleve Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 mg (per each): $0.12</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Anaprox DS Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">550 mg (per each): $11.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Mediproxen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 mg (per each): $0.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Naprosyn Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $7.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Naproxen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.08 - $0.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">375 mg (per each): $0.11 - $1.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.13 - $2.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Naproxen Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 mg (per each): $0.08 - $0.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">275 mg (per each): $2.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">550 mg (per each): $3.56 - $3.57</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867644"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suppository, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg/5 mL (40 mL, 474 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg [DSC], 250 mg, 375 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anaprox: 275 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anaprox DS: 550 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 275 mg, 550 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naprosyn: 375 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naxen EC: 250 mg, 375 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 375 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naprosyn: 750 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p></div>
<div class="block adm drugH1Div" id="F199834"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with food, milk, or antacids to decrease GI adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Shake suspension well before administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, delayed or extended release: Swallow tablet whole; do not break, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet, capsule, caplet, gelcap, oral suspension, and topical power formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, nonsteroidal anti-inflammatory drugs are not recommended for routine use after bariatric surgery. Where possible, use cyclooxygenase-2 selective therapy (celecoxib 100 to 200 mg up to twice a day). If enteric-coated/delayed-release formulations of naproxen are used after bariatric surgery, coadministration with proton pump inhibitor is advisable.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal suppository [Canadian product]: Insert suppository into rectum.</p></div>
<div class="block admp drugH1Div" id="F52613393"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food, milk, or antacids to decrease GI adverse effects.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Shake suspension well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Do not chew, crush, or break delayed- or controlled-release tablet; swallow whole.</p></div>
<div class="block meg drugH1Div" id="F7874744"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Anaprox: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F017581s115%2C018164s065%2C020067s024lbl.pdf%23page%3D23&amp;token=hMXBV8Zv2lDIWm9LQhihugE06hmQEwviKAWEXZKJxjOicGrxmZSUgrLTzuRqdpDliJPbxtAc%2FV3jtfU%2BFfb2%2FAw0gioY9%2FfpiQpBnHzqwMZljTlxRg5kumcYSinYb6%2Fxnh6o0L%2FnhfJ7x5FJkWJvAA%3D%3D&amp;TOPIC_ID=9682" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/017581s115,018164s065,020067s024lbl.pdf#page=23</a></p>
<p style="text-indent:-2em;margin-left:4em;">Anaprox DS, EC-Naprosyn, Naprosyn tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F017581s115%2C018164s065%2C020067s024lbl.pdf%23page%3D23&amp;token=hMXBV8Zv2lDIWm9LQhihugE06hmQEwviKAWEXZKJxjOicGrxmZSUgrLTzuRqdpDliJPbxtAc%2FV3jtfU%2BFfb2%2FAw0gioY9%2FfpiQpBnHzqwMZljTlxRg5kumcYSinYb6%2Fxnh6o0L%2FnhfJ7x5FJkWJvAA%3D%3D&amp;TOPIC_ID=9682" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/017581s115,018164s065,020067s024lbl.pdf#page=23</a></p>
<p style="text-indent:-2em;margin-left:4em;">Naprelan: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F020353s038lbl.pdf%23page%3D23&amp;token=AxfI8t7rB0PB0Et62Waf3zbCzTobobuec9e0mmkBCCz7Wv5x4uekz861NEfGEeaOrqaYP830jbAVpR%2FU7ITqMprnKENzH4yXrv1ui3L5E%2B%2FJ8lhwX0PM3sznqQCn8Aww&amp;TOPIC_ID=9682" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020353s038lbl.pdf#page=23</a></p>
<p style="text-indent:-2em;margin-left:4em;">Naprosyn suspension: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F018965s027lbl.pdf%23page%3D23&amp;token=GwTuJrgBz72ywL%2FyxoUQ60uyefFPCijSxnCf71ycTbGzaQKbEZi9VwR%2BWZD5mjebN6KIHaVHagOoilQcUlZM0YgCNSAbMVkyLViBq4Sz3qSBbuk8d0To3N1z0IyqvFzG&amp;TOPIC_ID=9682" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/018965s027lbl.pdf#page=23</a></p>
<p style="text-indent:-2em;margin-left:4em;">NSAID: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F017581s114%2C018164s064%2C020067s021lbl.pdf%23page%3D22&amp;token=VB%2FrjbAEGXN49OXcE9Zvbq4otXQMYG746OAjtVx4er3Oep0qqhjECMAflDTqiZFogwT%2Bh%2BJehf4rkgqrdY1eBYnDb2rd8B8b6onUkbtHmvp4F53LIc%2Fc2z1gHrfv%2Blm6f5KEB%2BVlyVXr25S3O9LNiA%3D%3D&amp;TOPIC_ID=9682" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017581s114,018164s064,020067s021lbl.pdf#page=22</a></p></div>
<div class="block use drugH1Div" id="F199833"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory:</b> Relief of the signs and symptoms of gout, ankylosing spondylitis, bursitis, polyarticular juvenile idiopathic arthritis (excluding ER tablets), osteoarthritis, rheumatoid arthritis, and tendinopathy. Delayed-release naproxen is not recommended for initial treatment of acute pain.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysmenorrhea, primary:</b> Treatment of primary dysmenorrhea. Delayed-release naproxen is not recommended for initial treatment of acute pain.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain and/or fever:</b> Relief of mild to moderate pain and/or fever. Delayed-release naproxen is not recommended for initial treatment of acute pain.</p></div>
<div class="block off-label drugH1Div" id="F25731116"><span class="drugH1">Use: Off-Label: Adult</span><p>Abnormal uterine bleeding, nonacute; Migraine, acute treatment</p></div>
<div class="block mst drugH1Div" id="F199915"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Naproxen may be confused with Natacyn, Nebcin</p>
<p style="text-indent:-2em;margin-left:4em;">Anaprox may be confused with Anaspaz, Avapro</p>
<p style="text-indent:-2em;margin-left:4em;">Naprelan may be confused with Naprosyn</p>
<p style="text-indent:-2em;margin-left:4em;">Naprosyn may be confused with Natacyn, Nebcin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Naproxen is identified in the Beers Criteria as a potentially inappropriate medication to be avoided for chronic use in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high-risk category (eg, older than 75 years or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). In addition, avoid for short-term scheduled use in combination with oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents unless alternatives are ineffective and patient can receive concomitant gastroprotective agent (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Flogen [Mexico] may be confused with Flovent brand name for fluticasone [US, Canada]</p>
<p style="text-indent:-2em;margin-left:4em;">Flogen [Mexico] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [US, Canada], and perfloxacin [Philippines]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F199900"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F199824"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Naproxen may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Naproxen may increase the serum concentration of Apixaban.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and naproxen. If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diflunisal: May enhance the adverse/toxic effect of Naproxen. Specifically, the risk for gastrointestinal toxicity may be increased. Diflunisal may enhance the antiplatelet effect of Naproxen. Diflunisal may decrease the excretion of Naproxen.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue nonsteroidal anti-inflammatory agents (NSAIDs) prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Ketorolac (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.  Management: Consider reducing the lithium dose when initiating a NSAID. Monitor for increased lithium therapeutic/toxic effects if a NSAID is initiated/dose increased, or decreased effects if a NSAID is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Avoid coadministration of higher dose methotrexate (such as that used for the treatment of oncologic conditions) and NSAIDs. Use caution if coadministering lower dose methotrexate and NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk for gastrointestinal toxicity is increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti-inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Avoid coadministration of pralatrexate with nonsteroidal anti-inflammatory drugs (NSAIDs). If coadministration cannot be avoided, closely monitor for increased pralatrexate serum levels or toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective).  Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Consider alternatives to this combination when possible. If the combination must be used, monitor coagulation status closely and advise patients to promptly report any evidence of bleeding or bruising.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F199850"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Naproxen absorption rate/levels may be decreased if taken with food. Management: Administer with food, milk, or antacids to decrease GI adverse effects. </p></div>
<div class="block rep_considerations drugH1Div" id="F49308487"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) may delay or prevent rupture of ovarian follicles. This may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in patients having difficulty conceiving or those undergoing investigation of fertility. In an observational study of couples planning a pregnancy, use of naproxen within the previous 4 weeks was associated with a reduced probability of becoming pregnant. Doses ≥1,500 mg had a greater reduction in fecundability than doses &lt;1,500 mg (McInerney 2017).</p>
<p style="text-indent:0em;margin-top:2em;">In an observational study of couples planning a pregnancy, cumulative doses of naproxen &lt;3,000 mg consumed by the male within the previous 4 weeks did not decrease the probability of fathering a child. Cumulative doses of naproxen ≥3,000 mg within the previous 4 weeks may decrease the probability of fathering a child; however, this was based on a limited number of patients and the results were imprecise (Wesselink 2020). Based on available data, NSAIDs can be continued in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F7696306"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Naproxen crosses the placenta (Brogden 1975; Siu 2002).</p>
<p style="text-indent:0em;margin-top:2em;">The use of nonsteroidal anti-inflammatory drugs (NSAIDs) close to conception may be associated with an increased risk of miscarriage due to cyclooxygenase-2 inhibition interfering with implantation (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Birth defects have been observed following in utero NSAID exposure in some studies; however, data are conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage, have been observed in the fetus/neonate following in utero NSAID exposure (Bermas 2014; Bloor 2013). Maternal NSAID use may cause fetal renal dysfunction leading to oligohydramnios. Although rare, this may occur as early as 20 weeks' gestation and is more likely to occur with prolonged maternal use. Oligohydramnios may be reversible following discontinuation of the NSAID (Dathe 2019; FDA 2020). In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Avoid maternal use of NSAIDs beginning at 20 weeks' gestation. If NSAID use is necessary between 20 and 30 weeks' gestation, limit use to the lowest effective dose and shortest duration possible; consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found (FDA 2020). Because NSAIDs may cause premature closure of the ductus arteriosus, product labeling for naproxen specifically states to avoid use starting at 30 weeks' gestation.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available information, NSAIDs can be continued during the first 2 trimesters of pregnancy in patients with rheumatic and musculoskeletal diseases; use in the third trimester is not recommended (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). The acute treatment of migraine headaches during pregnancy should be initiated with an agent other than a NSAID. If an NSAID is needed as second-line therapy, treatment should be limited to the second trimester and total duration of therapy should be no longer than 48 hours (ACOG 2022).</p>
<p style="text-indent:0em;margin-top:2em;">NSAIDs may be used as part of a multimodal approach to pain relief following cesarean delivery (ACOG 2019).</p></div>
<div class="block brc drugH1Div" id="F7696309"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Naproxen is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of naproxen in breast milk are available following maternal administration of oral naproxen 375 mg twice daily for 3 weeks to 1 woman ~6 months postpartum. Naproxen breast milk concentrations were 1.76 to 2.37 mcg/mL with the highest concentration occurring 4 hours after the dose. Naproxen was detected in the urine of the breastfeeding infant. The cumulative amount of naproxen found in the urine of the infant was 0.26% of the cumulative maternal urinary excretion (Jamali 1982; Jamali 1983).</p>
<p style="text-indent:-2em;margin-left:4em;">• Using a milk concentration of 2.37 mcg/mL, the estimated exposure to the breastfeeding infant would be 0.36 mg/kg/day (relative infant dose: 3.3% based on the weight adjusted maternal dose of 750 mg/day).</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when the relative infant dose (RID) is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">A prospective cohort study evaluated the outcomes of breastfed infants whose mothers were taking various medications. Within the study, 20 mother-infant pairs reported naproxen exposure (dose, duration, relationship to breastfeeding not provided). There were two cases of drowsiness and one case of vomiting in the breastfed infants (Ito 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Nonopioid analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred for breastfeeding patients who require pain control peripartum or for surgery outside of the postpartum period. Short-term use of naproxen is acceptable, but avoid long-term use (&gt;1 week) in breastfeeding patients (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]). NSAIDs are considered compatible for the treatment of rheumatic and musculoskeletal diseases (ACR [Sammaritano 2020]). NSAIDs may be used to treat acute migraine in lactating patients (ACOG 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Avoid maternal use of NSAIDs if the breastfeeding infant has platelet dysfunction, thrombocytopenia, or a ductal-dependent cardiac lesion (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]; Bloor 2013).</p></div>
<div class="block dic drugH1Div" id="F199840"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Sodium content: Naproxen sodium products contain about 50 mg (2 mEq) of sodium per 500 mg of naproxen. Naprosyn suspension contains 39 mg of sodium per 5 mL (125 mg). Consider this in patients whose overall intake of sodium must be severely restricted.</p></div>
<div class="block mop drugH1Div" id="F199828"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC (if hemoglobin ≤10 g at initiation, continue to monitor hemoglobin periodically during long-term therapy), chemistry profile (periodically during long-term therapy), LFTs, renal function tests (urine output, serum BUN and creatinine), BP (at initiation and during therapy), signs/symptoms of fluid retention, periodic ophthalmic exam (with any vision changes occurring during long-term therapy), signs of bleeding (occult or gross blood loss, especially in patients with coagulation disorders or who are receiving anticoagulants); monitor for anemia with long-term therapy; monitor for signs/symptoms of immediate or delayed hypersensitivity reactions.</p></div>
<div class="block pha drugH1Div" id="F199818"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties</p>
<p style="text-indent:0em;margin-top:2em;">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels. </p></div>
<div class="block phk drugH1Div" id="F199836"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Analgesic: 30 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Analgesic: &lt;12 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Almost 100% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 0.16 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: &gt;99% to albumin; increased free fraction in elderly </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively metabolized in the liver to 6-0-desmethyl naproxen; parent drug and desmethyl metabolite undergo further metabolism to their respective acylglucuronide conjugated metabolites </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 95%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children: Range: 8 to 17 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 8 to 14 years: 8 to 10 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: Normal renal function: 12 to 17 hours; Moderate-to-severe renal impairment: ~15 to 21 hours (Anttila 1980)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tablets, naproxen: 2 to 4 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tablets, naproxen sodium: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tablets, delayed-release (empty stomach): 4 to 6 hours; range: 2 to 12 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tablets, delayed-release (with food): 12 hours; range: 4 to 24 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suspension: 1 to 4 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suppository [Canadian product]: 2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (95%; primarily as metabolites); feces (≤3%)</p></div>
<div class="block phksp drugH1Div" id="F51154881"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Metabolites and conjugates may accumulate.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F199841"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apranax | Gibixen | Miranax | Narox | Nopain | Prodexin | Proxen</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Algioprux | Alidase | Alidase f | Causalon pro | Clavezona | Congex | Congex 24 | Debril | Fabralgina | Flaxvan | Flogocefal | Melgar | Monarit | Mox 12 HS | Mox Forte | Naprofidex | Naprogen | Naprontag | Naprontag gesic | Naproxeno Hlb | Naproxeno millet | Naproxeno northia | Naproxeno teva | Naproxeno Vannier | Naproxphar | Naprux | Naprux gesic | Neuralprona | Neuralprona 250 | Tundra | Veradol | Xicane | Xicane retard</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Miranax | Naprobene | Naproxen Genericon | Naproxen hcs | Naproxen krka | Nycopren | Proxen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Amcal period pain | Anaprox | Apohealth period pain relief | Blooms the chemist period pain relief | Chemists own period pain | Cipla femme perod pain relief | Cm chemagesic | Crysanal | Inza | Motriflex | Naprofem | Naprogesic | Naproleve | Naprosyn | Naproxen | O/n period pain | Pain relief naproxen | Period pain | Period pain relief | Pharmacy action period pain relief | Pharmacy care period pain relief | Pharmacy choice period pain relief | Proxen | Soul Pattinson Naproxen | Wagner Health Period Pain Relief</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aktivex | Anaflex | Diproxen | Ecless | Ecless sr | Gloxen | Naid | Napasin | Napier | Napium | Napoxen | Napro | Napro-a | Naprocid | Napronil | Napropain | Naproson | Naprosyn | Naprox | Naproxen | Naproxin | Napryn | Napsod | Naspro | Naxin | Nipoxen | Novaxen | Npx | Nuprafen | Nupralgin | Nx 1 | Pairox | Proxen | Ranoxen | Releve | Repro | Servinaprox | Sonap | Ticoflex | Tofa | Ultranax | Venoxen | Xenapro | Zenosyn</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Apranax | Naproflam | Naprosyne | Naproxen ab | Naproxen hcs | Naproxene eg | Nycopren | Toproxen</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Apranax | Etrixenal | Nalgesin</span>;</li>
<li>
<span class="countryCode">(BO)</span> <span class="country">Bolivia, Plurinational State of</span><span class="countrySeparator">: </span><span class="drugName">Calmitol n</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Flamaprox | Flanax | Flanax xr | Naproflen | Napronax | Naprosyn | Naprox | Naproxeno | Naproxeno sodico | Naxotec | Nexflen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Apranax | Naprosyn | Naproxen mepha | Nycopren | Proxen</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Algixene</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Atac | Deucoval | Eurogesic | Flanax | Flogotone | Naprogesic | Naprosyn | Naproxeno | Reprost | Triox</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao pu li | Bei li | Bu sheng | Jin kang pu li | Naproxen | Napton | Shi luo te | Slowt</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ainedap | Ainedap flash | Ainedap forte | Alinax | Analper Nax | Aprodol | Aprodol forte | Apronax | Benpropen | Blocdol bx | Clofedoc | Colfem | Doliflam nax | Durafex | Durafex f | Durafex forte | Flaxul | Improstan | Infor | Naproflash | Naprosyn | Naprox | Naproxeno | Naproxeno La Sante | Naproxeno mk | Naproxeno sodico | Naxtridol | Perclusone | Ponstan Max | Proxenil | Sanadol | Suprim D | Vencedol | Wintrex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Apo naproxen | Apranax | Etrixenal | Nalgesin | Nalgesin s | Naprobene | Naprosyn | Naproxen apotex | Naproxen dh | Napsyn</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alacetan Nna | Aleve | Apranax | Dolormin fur fraue.bei menst.beschwe.m.naprox | Dolormin Gs mit Naproxen | Malexin | Mobilat schmerztabletten | Naprocutan | Naproflam | Naprostad | Naproxen 1 A Pharma | Naproxen Acis | Naproxen al | Naproxen Aristo | Naproxen axi | Naproxen axicur | Naproxen Grunenthal | Naproxen hormosan | Naproxen Lindopharm | Naproxen ratiopharm | Naproxen Sandoz | Naproxen Schwoerer | Naproxen stada | Naproxiwieb | Prodolor | Proxen | Togal Naproxen</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Aleve max | Apranax | Dafloxen | Flamantil | Flanax | Luproxeno | Mioxen | Nafar | Naprosyn | Naproxeno | Naxen | Proflex | Pronoflex | Sanaxen</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acroxen | Apronax | Aproxen | Dolonex | Fabogesic nax | Flanax | Infor | Iraxen | Nagesol forte | Naprodex | Naproflex | Naprolive | Naprosyn | Naprotofis | Naproxen | Naproxeno | Naproxeno mk | Odontogesic | Paraxflan | Patropan | Pronol | Prox | Servinaprox | Sindolan S | Sobronil</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Daprox | Epromul | Nalgesin | Nalgesin forte | Nalgesin s | Naprosyn | Nycopirin | Sanaprox</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Apranax | Myoprox | Naleve | Naprofen | Naprogesic | Naprosyn | Prodexin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Aliviomas | Antalgin | Denaxpren | Lundiran | Momen | Naprosyn | Naproval | Naproxen ratiopharm | Naproxeno aristo | Naproxeno aurobindo | Naproxeno aurovitas | Naproxeno Normon | Naproxeno ratiopharm | Naproxeno sodico aurovitas | Naproxeno sodico cinfa | Naproxeno sodico Kern Pharma | Naproxeno sodico tad | Proxen | Tacron</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Alpoxen | Eox | Miranax | Nalgesin | Naprometin | Napromex | Naprosyn | Naproxen krka | Naxopren | Nycopren | Pronaxen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aleve | ALEVETABS | Antalnox | Apranax | Naprosyne | Naproxene sodique eg | Naproxene teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Apranax fort | Arthrosin | Arthroxen | Feminax ultra | Kenosyn | Laraflex | Naprosyn | Naproxen | Naproxen Almus | Naproxen arrow | Naproxen berk | Naproxen cox | Naproxen dc | Naproxen kent | Naproxen sandoz | Naproxen steinhard | Nycopren | Nycopren nye | Pranoxen | Rheuflex | Synflex | Timpron | Valrox</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Anaprox | Naprosyn | Nycopren e</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo napro na | Apo naproxen | Cp-Naproxen | Inza | Napmel | Napro-eaze | Naprorex | Naprosyn | Naproxen Vickmans | Napxen | Proxen | Sinton | Soden | Syn-Naproxen</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Nalgesin | Nalgesin L | Nalgesin Relief | Nalgesin s</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Analgesin | Analgesin dolo | Analgesin forte | Apranax | Apranax dolo | Etrixenal | Huma-naprox | Naprosyn | Naproxen-b | Servinaprox</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Antalgin | Danaprox | Gesiprox | Naxen | Prafena | Xenifar</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Gerinap | Napmel | Naprex | Naprosyn | Synflex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Aponacin | Naprex | Naproxi | Narocin | Naxyn | Point</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Artagen | Movibon | Napexar | Napra s | Naprosyn | Xenar | Xenobid</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Naprokin | Napron | Naprosam | Naproxdain</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Alganil | Algonapril | Axer alfa | Floginax | Floxalin | Gibixen | Laser | Leniartril | Momendol | Napreben | Naprius | Naprodol | Naprorex | Naprossene Angelini | Naprossene sodico doc generici | Naprosyn | Naproxene | Naproxene sodico dorom | Naproxene sodico hcs | Neo eblimon | Numidan | Prexan | Primeral | Synalgo | Synflex | Uninapro | Xenar</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Nexorpan | Noxen | Prodexin | Proxen | Proxidol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amon | Monocloton taisho | Monocloton teikoku | Naixan | Naproxen nipro | Naropp | Narostin | Narostin sanken | Rahsen | Saritilron | Tohxen</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Naprin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acepen | Allnapen | Alsaxen | Althaxen | Anaflox | Anafu z | Analap | Anaprox | Anataxim | Anax | Anexen | Aprogen naproxen na | Aproxen | Axen | Babel | Carol n | Ceroxen | Coolmin | Danapro | Danaproxen | Danaxen | Disapain | Dispain | Dongindang naproxen | Enfriend | Ethyroxen | Ezn 6 strong | Free nf | Hanipa | Hwakpen | Il yang naproxen sodium | Jynal | Jynal q | Kicksen | Lacpina | Licorax | Lozen | Maxen | Mirae naproxen sodium | Morningpen | Morningphen | N friend | Naegen | Nafucen | Nalexin | Nalox | Nanarox | Nap oneq | Naphlong | Napnopen | Napolon | Napone qs | Napoxen | Napren | Naprex | Naprin | Naprong | Naprosyn | Naprox | Naproxen | Naproxen myungmoon | Naproxin | Naproxo | Napxen | Naquron | Narexine | Narixen | Naropen | Narox | Naroxpen | Nassen | Natsen | Naxen | Naxen-f | Naxen-f sr | Pain angel xen | Paincool | Parkxen | Pharmpain power | Plamen | Poxen | Prina | Prixen | Pronax | Pros | Protrin | Puroxoc | Q sen | Quicksen | Rumasen | Sennar | Seroxen | Sinflex | Sinflex semi | Snofin | Snopin | Soluroxen | Sopoxen | Soren | Spiroxen | Synflex | Synflex semi | Taksen | Taxon | Theraroxen | Tonkeeper a | Xenfen | Zenar | Zynal | Zynal q</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo napro na | Miranax | Nopain | Proxen</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apranax | Naprorex | Naproxen Genericon | Naproxene sodique arrow | Proxen</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo naproxen | Apranax | Epromul | Momendol | Nalgesin | Naprosyn | Napsyn | Proxen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Apranax | Naprosyne</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apo naproxen | Apranax | Daprox | Dolormin Gs mit Naproxen | Epromul | Nalgedol | Nalgesin | Naprosyn | Naproxen stada | Napsyn | Proxen | Sanaprox</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Algixene | Apranax | Naprosyne</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Actiquim | Alebrem | Algiprox | Alliviax | Analgen | Anapsyl | Apronax | Arsenal | Bioxan | Bixen | Bruproxen | Dafloxen | Dartrox | Deflamox | Diferbest | Divadays | Dolxen | Edem | Faraxen | Flanax | Flanax 660 | Flavoxen | Flaxendol | Flexen | Flexogen | Flogen | Fuxen | Genax | Genoflam | Genoxen | Inflanox | Iqfasol | Lacerdem | Lidolex | Messelxen | Naflapen | Napoxol | Naproxeno | Naproxeno g.i | Naproxeno protein | Naproxeno psicofarma | Naproxeno silanes | Naproxeno Teva | Nasocan | Navixen | Naxen | Neonaxil | Nixal | Novaxen | Noxil | Ormoxen | Pactens | Petex | Praxedol | Profaxen | Pronaxil | Propional | Proxalin | Proxem | Salupran | Sedacaps | Sertrixen | Sodaxtan | Sodixen | Sonavic | Tandax | Unirelaxed | Vantin | Velsay</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo napro na | Apo naproxen | Arthrosyn | Dynaflex | Hoproxen | Naproscan | Naprosic | Naprosyn | Pp naproxen na | Safrosyn | Safrosyn S | Seladin | Sonap | Sunprox | Synflex</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Exus naproxen | N &amp; n naproxen | Naproflex | Naxen | Raprox | Relaflex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Aleve Classic bij pijn en koorts | Aleve feminax | Aleve Select | Etos naproxennatrium | Naprocoat | Naprosyne | Naprovite | Naprovite 275 | Naproxen | Naproxen accord | Naproxen CF | Naproxen na | Naproxen ratiopharm | Naproxen-fxp | Naproxennatrium | Nycopren</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Alpoxen | Bonyl | Ledox | Ledox-e | Napren | Napren-e | Naprosyn | Naprosyn Entero | Naproxen al | Naproxen evolan | Naproxen mylan | Naproxen norfri | Naproxen orion | Proxan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Naprogesic | Naprosyn | Naxen | Noflam | Noflam N | Sonaflam | Synflex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Aflamax | Aflaxil | Aleve | Apo naproxeno | Aprodol | Aproforte | Apromedix | Apron f | Apronax | Apronax mujer | Aproxen | Aproxil | Aproxx brand | Assonax | Beckanflam | Bionax | Complement | Desinflam | Diconaxx | Dologina | Dolomejoral | Dolomes | Doloproxen | Doprox | Flonax | Iraxen | Lexinax | Maxiflam | Naledyn Sodico | Naprocop | Naprocop M | Naprodel | Naprofas | Naprol | Napromed | Naproplus | Naprosyn | Naproxal | Naproxcoll | Naproxeno | Naproxeno sodico | Naproxeno sodico fmndtria | Naproxflam | Naproxpharma | Naproxport | Naxodol | Neoflam | Nopramax | Nopraxin | Novanax | Odontogesic | P nax | Painflex | Ponstan RD | Promaxxfarma | Promizem | Proxidol | Proxidol a | Sincolic mujer | Uniflam | Wintrex</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Agapro | Flacidon | Naflax | Napren | Naprokin | Naprosyn | Naproxen | Naproxen Am-Europharma | Naxen | Pharex Naproxen | Reumax | Sanomed | Saphroxen | Sarimax | Skelan | Sonap | Syproxen | Xen-aid</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alcuflex | Alidase | Anaprox | Apranax | Aprogesic | Aproxen | Artic | Avenax | Bio prox | Bloxen | Calgesic | Citiflex | Compan | Cosnap | Dephlog | Deprelan | Dolonap | Dolosyn | Dolotec | Dolotec sr | Ephanax | Eroxen | Esmov | Fanroxib | Flexin | Fonza | Genoxen | Gia | Mayoflex | Mb-roxen | Menogesic | Miramax | N sodi | Naerex | Nalium | Nap | Napex | Napgesic | Naplis | Naplis sr | Napnor | Napolive | Napreben | Naprelan | Naprin | Naprium | Napro-heim | Naprocil | Naprofast | Napromor | Naprosyn | Naprox | Naprozen | Naprozone | Naps | Napson | Naptrol | Narone | Neoprox | Nepexen | Nepra | Noral | Novalit | Nunap | Nurmed | Orthoxen | Painap | Panarodin | Promig | Propex | Prosyn | Provin | Proxen | Rheprox | Rhynox | Rokflex | Roman | Santosa | Sonac | Torex ir | Tormax | Uni nex | Xanbid | Xenar | Xenker | Xeron | Xynap | Zenap | Zynap</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Anapran | Anapran neo | Apo napro | Apo napro fast | Apo naproxen | Apranax | Boloxen | Nalgesin | Napritum | Naprosyn | Naprosyne | Naproxen | Naproxen Genoptim | Natrax | Naxii | Pabi naproxen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Aleve Arthritis | Aleve back &amp; muscle pain | Anaprox | Anaprox ds | EC Naproxen | EC-Naprosyn | Mediproxen | Naprelan | Naprosyn | Naproxen Delayed Release | Naproxen sod | Naproxen sodium controlled release | Pamprin all day</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ilgesin | Momendol | Naprosyn | Naproxeno | Naproxeno generis | Naproxeno generis gastroresistentes | Naproxeno germed | Naproxeno krka | Reuxen</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Clerinax | Donixal | Eurogesic adulto | Eurogesic adulto forte | Naprosyn | Nazep | Noflame</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Naprosyn EC | Naprox | Narox (NPI) | Nopain | Nopain DS | Proxen | Proxidol | Proxidol DS</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Etrixenal | Naldorex | Naprosyn | Naproxen aurobindo | Reuxen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Algezir ultra | Apo naproxen | Motrin | Nalgesin | Nalgesin forte | Naprobene | Naprosyn | Naproxen acre | Naproxen-akr | Niaproff | Pentalgin mono | Theraleve</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo naproxen | Miranax | Naprotex | Naprox | Nopain | Proxen | Riaproxen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alpoxen | Eox | Ipaflex | Miranax | Naprocur | Naprosyn | Naprosyn Entero | Naproxen 2care4 | Naproxen abece | Naproxen apofri | Naproxen astrazeneca | Naproxen bmm pharma | Naproxen ebb | Naproxen evolan | Naproxen merck nm | Naproxen mylan | Naproxen Nordic | Naproxen Orifarm | Pronaxen</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Anax | Apo napro na | Gesiprox | Inza | Naprosyn | Noflam N | Seladin | Soden | Soproxen | Soren | SP Anflam | Sunprox | Synflex | Zynal</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Emoxen | Nalgesin | Nalgesin s | Naprosyn</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Etrixenal | Nalgesin | Nalgesin s | Naprosyn | Napsyn</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anaproxen | Annoxen-s | Bemednapro | Buproxen | Daproxen | Maproxen | Napoxin | Naprofazt | Naproflex | Napronac | Naprosian | Naproso | Naprosyn | Naprosyn le | Naprozac | Napsen | Napxa | Napxen | Napxon | Nasin | Nasynmed | Naxyn | Neoflex | Neoxen | Ostexin | Polyxen | Poxenca | Prodaril n | Proxen | Serviproxan | Sonap | Soproxen | Synflex | Synogin | Tendosin | Topxen | U-proxyn</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Apranax | Axer | Naprosyne | Nipral | Nopain | Noxen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">A-nox | Anaprotab | Apraljin | Apranax | Apraxin | Aprodent | Aprol | Aprowell | Armanaks | Atren | Bonmin | Exvile | Floneks | Inaprol | Kapnax | Karoksen | Naponal | Napradol | Napren | Napren s | Naprodex | Naprosyn | Naprotab | Opraks | Relokap | Romaksen | Rumazolidin | Synax | Syndol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anaprox | Genuproxin | Honlow | Monochroton | Nafxen | Nagenton | Naloxen | Naposin | Napoton | Napoxen | Naprocide | Naproxin | Naprozen | Napton | Napusin | Naputon | Naroton | Naroxin | Naton | Natoxen | Naxen | Neoproxen | Novo naprox | Noyan | Protacin | Prox | Proxen | Proxin | Seladin | Sinton | Sutolin | Sutony | U-ritis | Winpron | Xenar</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Anapran | Nalgesin | Nalgesin forte | Naproff | Naprosyn | Naproxen</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aleve | Alidase | Alufren | Dolorex | Medilor | Naproxeno</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Apranax | Apronax | Naproxeno | Naproxeno sodico | Rogalin | Synaprosyn</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Propain</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Acusprain | Adco-naproxen | Aleve | Aspen Naproxen | Be-tabs naproxen | Bio Naproxen | Compu naproxen | Fibroxyn | Mer-naproxen | Merck-naproxen | Micro Naproxen | Motriflex | Nafasol | Nafasol ec | Napflam | Naproscript | Rolab-naproxen | Synflex</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Apo naproxen | Naproscript</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. <i>Circulation</i>. 2010;122(24):2619-2633. doi:10.1161/CIR.0b013e318202f701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6731494">
<a name="6731494"></a>Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. <i>Am J Nephrol</i>. 1984;4(1):1-6. doi:10.1159/000166764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/6731494/pubmed" id="6731494" target="_blank">6731494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aleve caplets (naproxen) [prescribing information]. Bayer Healthcare; May 2014.</div>
</li>
<li>
<div class="reference">
                  Aleve liquid gels (naproxen) [prescribing information]. Bayer Healthcare; January 2015.</div>
</li>
<li>
<div class="reference">
                  Aleve tablets (naproxen) [prescribing information]. Bayer Healthcare; May 2014.</div>
</li>
<li>
<div class="reference">
                  Aleve tablets (naproxen) [prescribing information]. Whippany, NJ: Bayer; received 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29891025">
<a name="29891025"></a>Alqahtani Z, Jamali F. Clinical outcomes of aspirin interaction with other non-steroidal anti-inflammatory drugs: a systematic review. <i>J Pharm Pharm Sci</i>. 2018;21(1s):29854. doi:10.18433/jpps29854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/29891025/pubmed" id="29891025" target="_blank">29891025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3723650">
<a name="3723650"></a>Alun-Jones E, Williams J. Hyponatremia and Fluid Retention in a Neonate Associated With Maternal Naproxen Overdosage. <i>J Toxicol Clin Toxicol</i>. 1986;24(3):257-260.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/3723650/pubmed" id="3723650" target="_blank">3723650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 209: Obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225. doi:10.1097/AOG.0000000000003132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Pain Society (APS). <i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 7th ed. Glenview, IL: 2016.</div>
</li>
<li>
<div class="reference">
                  Anaprox and Anaprox DS (naproxen sodium) [product monograph]. Brantford, Ontario, Canada: Methapharm Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2650879">
<a name="2650879"></a>Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gøtzsche PC. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. <i>Cephalgia</i>. 1989;9(1):29-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2650879/pubmed" id="2650879" target="_blank">2650879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3115366">
<a name="3115366"></a>Andrejak M, Davion T, Gineston JL, Capron JP. Cross hepatotoxicity between non-steroidal anti-inflammatory drugs. <i>Br Med J (Clin Res Ed)</i>. 1987;295(6591):180-181. doi:10.1136/bmj.295.6591.180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/3115366/pubmed" id="3115366" target="_blank">3115366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014;109(6):811-819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7439246">
<a name="7439246"></a>Anttila M, Haataja M, Kasanen A. Pharmacokinetics of naproxen in subjects with normal and impaired renal function. <i>Eur J Clin Pharmacol</i>. 1980;18(3):263-268. doi:10.1007/BF00563009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/7439246/pubmed" id="7439246" target="_blank">7439246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16813969">
<a name="16813969"></a>Aranda JV, Thomas R. Systematic review: intravenous Ibuprofen in preterm newborns. <i>Semin Perinatol</i>. 2006;30(3):114-120. doi:10.1053/j.semperi.2006.04.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/16813969/pubmed" id="16813969" target="_blank">16813969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32479922">
<a name="32479922"></a>Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? <i>Am J Kidney Dis</i>. 2020;76(4):546-557. doi:10.1053/j.ajkd.2020.03.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/32479922/pubmed" id="32479922" target="_blank">32479922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15668365">
<a name="15668365"></a>Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. <i>Arch Intern Med</i>. 2005;165(2):189-192. doi:10.1001/archinte.165.2.189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15668365/pubmed" id="15668365" target="_blank">15668365</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Becker MA. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 5, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21640290">
<a name="21640290"></a>Bell AD, Roussin A, Cartier R, et al. The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. <i>Can J Cardiol</i>. 2011;27(suppl A):1-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/21640290/pubmed" id="21640290" target="_blank">21640290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12362012">
<a name="12362012"></a>Berde CB, Sethna NF. Analgesics for the treatment of pain in children. <i>N Engl J Med</i>. 2002;347(14):1094-1103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/12362012/pubmed" id="12362012" target="_blank">12362012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24663106">
<a name="24663106"></a>Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340. doi:10.1097/BOR.0000000000000054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/24663106/pubmed" id="24663106" target="_blank">24663106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23726390">
<a name="23726390"></a>Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. <i>Lancet</i>. 2013;382(9894):769-779. doi:10.1016/S0140-6736(13)60900-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23726390/pubmed" id="23726390" target="_blank">23726390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682313">
<a name="24682313"></a>Bhangu A, Singh P, Fitzgerald JE, Slesser A, Tekkis P. Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and experimental studies. <i>World J Surg</i>. 2014;38(9):2247-2257. doi:10.1007/s00268-014-2531-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/24682313/pubmed" id="24682313" target="_blank">24682313</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation</i>. 2008a;118(18):1894-1909. doi:10.1161/CIRCULATIONAHA.108.191087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/18836135/pubmed" id="18836135" target="_blank">18836135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19017521">
<a name="19017521"></a>Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>J Am Coll Cardiol</i>. 2008b;52(18):1502-1517.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/19017521/pubmed" id="19017521" target="_blank">19017521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21705120">
<a name="21705120"></a>Bhave G, Neilson EG. Volume depletion versus dehydration: how understanding the difference can guide therapy. <i>Am J Kidney Dis</i>. 2011;58(2):302-309. doi:10.1053/j.ajkd.2011.02.395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/21705120/pubmed" id="21705120" target="_blank">21705120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26841325">
<a name="26841325"></a>Blanca-López N, Pérez-Alzate D, Andreu I, et al. Immediate hypersensitivity reactions to ibuprofen and other arylpropionic acid derivatives. <i>Allergy</i>. 2016;71(7):1048-1056. doi:10.1111/all.12855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/26841325/pubmed" id="26841325" target="_blank">26841325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23558845">
<a name="23558845"></a>Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23558845/pubmed" id="23558845" target="_blank">23558845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31535715">
<a name="31535715"></a>Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. <i>Cochrane Database Syst Rev</i>. 2019;9(9):CD000400. doi:10.1002/14651858.CD000400.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/31535715/pubmed" id="31535715" target="_blank">31535715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12512867">
<a name="12512867"></a>Brix AE. Renal papillary necrosis. <i>Toxicol Pathol</i>. 2002;30(6):672-674. doi:10.1080/01926230290166760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/12512867/pubmed" id="12512867" target="_blank">12512867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1097233">
<a name="1097233"></a>Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Naproxen: a review of its pharmacological properties and therapeutic efficacy and use. <i>Drugs</i>. 1975;9(5):326-363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/1097233/pubmed" id="1097233" target="_blank">1097233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2034249">
<a name="2034249"></a>Brooks PM, Day RO. Nonsteroidal Anti-inflammatory Drugs - Differences and Similarities. <i>N Engl J Med</i>. 1991;324(24):1716-1725.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2034249/pubmed" id="2034249" target="_blank">2034249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23453549">
<a name="23453549"></a>Brophy PD. Changing the paradigm in pediatric acute kidney injury. <i>J Pediatr</i>. 2013;162(6):1094-1096. doi:10.1016/j.jpeds.2013.01.065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23453549/pubmed" id="23453549" target="_blank">23453549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15837265">
<a name="15837265"></a>Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects. <i>J Am Coll Cardiol</i>. 2005, 45(8):1295-1301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15837265/pubmed" id="15837265" target="_blank">15837265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15037526">
<a name="15037526"></a>Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. <i>Circulation</i>. 2004;109(12):1468-1471. doi:10.1161/01.CIR.0000124715.27937.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15037526/pubmed" id="15037526" target="_blank">15037526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11752357">
<a name="11752357"></a>Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. <i>N Engl J Med</i>. 2001; 345(25):1809-1817.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11752357/pubmed" id="11752357" target="_blank">11752357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11509629">
<a name="11509629"></a>Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. <i>J Immunol</i>. 2001;167(5):2831-2838. doi:10.4049/jimmunol.167.5.2831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11509629/pubmed" id="11509629" target="_blank">11509629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16534006">
<a name="16534006"></a>Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. <i>Circulation</i>. 2006;113(12):1578-1587. doi:10.1161/CIRCULATIONAHA.105.595793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/16534006/pubmed" id="16534006" target="_blank">16534006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33238721">
<a name="33238721"></a>Chang RW, Tompkins DM, Cohn SM. Are NSAIDs safe? Assessing the risk-benefit profile of nonsteroidal anti-inflammatory drug use in postoperative pain management. <i>Am Surg</i>. 2021;87(6):872-879. doi:10.1177/0003134820952834<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/33238721/pubmed" id="33238721" target="_blank">33238721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11964481">
<a name="11964481"></a>Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. <i>Science</i>. 2002;296(5567):539-541. doi:10.1126/science.1068711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11964481/pubmed" id="11964481" target="_blank">11964481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28488978">
<a name="28488978"></a>Chong I, Chao A. Stevens-Johnson syndrome/toxic epidermal necrolysis and treatment with a biologic: a case report. <i>Perm J</i>. 2017;21:16-060. doi:10.7812/TPP/16-060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/28488978/pubmed" id="28488978" target="_blank">28488978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26827847">
<a name="26827847"></a>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council [published correction appears in <i>J Pain</i>. 2016a;17(4):508-510]. <i>J Pain</i>. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/26827847/pubmed" id="26827847" target="_blank">26827847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26945352">
<a name="26945352"></a>Chou CI, Shih CJ, Chen YT, et al. Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: a nested case-control cohort study. <i>Medicine (Baltimore)</i>. 2016b;95(9):e2645. doi:10.1097/MD.0000000000002645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/26945352/pubmed" id="26945352" target="_blank">26945352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6731166">
<a name="6731166"></a>Clinch D, Banerjee AK, Ostick G. Absence of abdominal pain in elderly patients with peptic ulcer. <i>Age Ageing.</i> 1984;13(2):120-123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/6731166/pubmed" id="6731166" target="_blank">6731166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6363936">
<a name="6363936"></a>Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. <i>N Engl J Med</i>. 1984;310(9):563-572. doi:10.1056/NEJM198403013100905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/6363936/pubmed" id="6363936" target="_blank">6363936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10988282">
<a name="10988282"></a>Conlin P, Moore T, Swartz S, et al. Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients. <i>Hypertension</i>. 2000;36(3):461-465.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/10988282/pubmed" id="10988282" target="_blank">10988282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626023">
<a name="9626023"></a>Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. <i>Am J Med</i>. 1998;104(5):413-421. doi:10.1016/s0002-9343(98)00091-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/9626023/pubmed" id="9626023" target="_blank">9626023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31273431">
<a name="31273431"></a>Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. <i>Eur J Clin Pharmacol</i>. 2019;75(10):1347-1353. doi:10.1007/s00228-019-02712-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/31273431/pubmed" id="31273431" target="_blank">31273431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24733305">
<a name="24733305"></a>Davidson BL, Verheijen S, Lensing AW, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. <i>JAMA Intern Med</i>. 2014;174(6):947-953. doi:10.1001/jamainternmed.2014.946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/24733305/pubmed" id="24733305" target="_blank">24733305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9113437">
<a name="9113437"></a>Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. <i>Clin Pharmacokinet</i>. 1997;32(4):268-293. doi:10.2165/00003088-199732040-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/9113437/pubmed" id="9113437" target="_blank">9113437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29799625">
<a name="29799625"></a>Delzer LM, Golightly LK, Kiser TH, Biggins SW, Lewis VJ, Kim II. Calcineurin inhibitor and nonsteroidal anti-inflammatory drug interaction: implications of changes in renal function associated with concurrent use. <i>J Clin Pharmacol</i>. 2018;58(11):1443-1451. doi:10.1002/jcph.1264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/29799625/pubmed" id="29799625" target="_blank">29799625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17715646">
<a name="17715646"></a>Demirag MD, Ozenirler S, Goker B, Poyraz A, Haznedaroglu S, Ozturk MA. Idiosyncratic toxic hepatitis secondary to single dose of naproxen. <i>Acta Gastroenterol Belg</i>. 2007;70(2):247-248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/17715646/pubmed" id="17715646" target="_blank">17715646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22585767">
<a name="22585767"></a>Derosier FJ, Lewis D, Hershey AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. <i>Pediatrics</i>. 2012;129(6):e1411-1420.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/22585767/pubmed" id="22585767" target="_blank">22585767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11123786">
<a name="11123786"></a>De Silva B, Banney L, Uttley W, Luqmani R, Schofield O. Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis. <i>Pediatr Dermatol</i>. 2000;17(6):480-483. doi:10.1046/j.1525-1470.2000.01827.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11123786/pubmed" id="11123786" target="_blank">11123786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11199661">
<a name="11199661"></a>Dionne R. Additive Analgesia Without Opioid Side Effects. <i>Compend Contin Educ Dent</i>. 2000;21(7):572-574, 576-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11199661/pubmed" id="11199661" target="_blank">11199661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11603504">
<a name="11603504"></a>Dionne RA, Berthold CW. Therapeutic Uses of Nonsteroidal Anti-inflammatory Drugs in Dentistry. <i>Crit Rev Oral Biol Med</i>. 2001;12(4):315-330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11603504/pubmed" id="11603504" target="_blank">11603504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21834936">
<a name="21834936"></a>Doña I, Blanca-López N, Jagemann LR, et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. <i>Allergy</i>. 2011;66(11):1428-1433. doi:10.1111/j.1398-9995.2011.02684.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/21834936/pubmed" id="21834936" target="_blank">21834936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26991794">
<a name="26991794"></a>Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. <i>Br J Clin Pharmacol</i>. 2016;82(1):238-248. doi:10.1111/bcp.12938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/26991794/pubmed" id="26991794" target="_blank">26991794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10951654">
<a name="10951654"></a>Drugs for Pain. <i>Med Lett Drugs Ther</i>. 2000;42(1085):73-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/10951654/pubmed" id="10951654" target="_blank">10951654</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  EC-Naprosyn, Naprosyn, Anaprox DS (naproxen) tablets [prescribing information]. Alpharetta, GA: Canton Laboratories LLC; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19708964">
<a name="19708964"></a>Evers S, Afra J, Frese A, et al; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. <i>Eur J Neurol</i>. 2009;16(9):968-981.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/19708964/pubmed" id="19708964" target="_blank">19708964</a>]</span>
<span class="doi">10.1111/j.1468-1331.2009.02748.x</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23098967">
<a name="23098967"></a>Ferraris VA, Saha SP, Oestreich JH, et al. 2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. <i>Ann Thorac Surg</i>. 2012;94(5):1761-1781.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23098967/pubmed" id="23098967" target="_blank">23098967</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. <i>Arthritis Care Res (Hoboken)</i>. 2020;72(6):744-760. doi:10.1002/acr.24180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/32391934/pubmed" id="32391934" target="_blank">32391934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3540871">
<a name="3540871"></a>Forbes JA, Keller CK, Smith JW, et al. Analgesic Effect of Naproxen Sodium, Codeine, a Naproxen-Codeine Combination and Aspirin on the Postoperative Pain of Oral Surgery. <i>Pharmacotherapy</i>. 1986;6(5):211-218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/3540871/pubmed" id="3540871" target="_blank">3540871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Frank.2018">
<a name="Frank.2018"></a>Frank J, Poblete-Gutiérrez PA, Lang E. Porphyria. In: Bolognia JL, Schaffer JV, Cerroni L, eds. <i>Dermatology</i>. 4th ed. Elsevier; 2018:chap. 49<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/Frank.2018/pubmed" id="Frank.2018" target="_blank">Frank.2018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1872778">
<a name="1872778"></a>Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. <i>Aust N Z J Obstet Gynaecol</i>. 1991;31(1):66-70. doi:10.1111/j.1479-828x.1991.tb02769.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/1872778/pubmed" id="1872778" target="_blank">1872778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gaffo AL. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25247621">
<a name="25247621"></a>Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. <i>Immunohematology</i>. 2014;30(2):66-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/25247621/pubmed" id="25247621" target="_blank">25247621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15476911">
<a name="15476911"></a>Géraud G, Lantéri-Minet M, Lucas C, Valade D; French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. <i>Clin Ther</i>. 2004;26(8):1305-1318. doi:10.1016/s0149-2918(04)80161-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15476911/pubmed" id="15476911" target="_blank">15476911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18359332">
<a name="18359332"></a>Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. <i>Am J Cardiol</i>. 2008;101(7):1060-1063. doi:10.1016/j.amjcard.2007.11.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/18359332/pubmed" id="18359332" target="_blank">18359332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15809462">
<a name="15809462"></a>Goldenberg NA, Jacobson L, Manco-Johnson MJ. Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen. <i>Ann Intern Med</i>. 2005;142(7):506-509. doi:10.7326/0003-4819-142-7-200504050-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15809462/pubmed" id="15809462" target="_blank">15809462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17349452">
<a name="17349452"></a>Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. <i>Am J Med</i>. 2007;120(3):280.e1-280.e2807. doi:10.1016/j.amjmed.2006.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/17349452/pubmed" id="17349452" target="_blank">17349452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15705456">
<a name="15705456"></a>Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. <i>Lancet</i>. 2005;365(9458):475-481. doi:10.1016/S0140-6736(05)17864-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15705456/pubmed" id="15705456" target="_blank">15705456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2642452">
<a name="2642452"></a>Graham DY. Prevention of Gastroduodenal Injury Induced by Chronic Nonsteroidal Anti-inflammatory Drug Therapy. <i>Gastroenterology</i>. 1989;96(2, pt 2)(suppl):675-681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2642452/pubmed" id="2642452" target="_blank">2642452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32944113">
<a name="32944113"></a>Guerrero Gómez DA, París Zorro S, Aponte Barrios W, Carrillo Bayona JA. Drug reaction with eosinophilia and systemic symptoms (DRESS) with severe and atypical lung involvement. <i>Radiol Case Rep</i>. 2020;15(11):2178-2182. doi:10.1016/j.radcr.2020.08.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/32944113/pubmed" id="32944113" target="_blank">32944113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23325533">
<a name="23325533"></a>Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. <i>Drug Saf</i>. 2013;36(2):135-144. doi:10.1007/s40264-012-0013-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23325533/pubmed" id="23325533" target="_blank">23325533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30112779">
<a name="30112779"></a>Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study. <i>Pharmacoepidemiol Drug Saf</i>. 2018;27(11):1174-1181. doi:10.1002/pds.4640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/30112779/pubmed" id="30112779" target="_blank">30112779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18174091">
<a name="18174091"></a>Gunner KB, Smith HD, Ferguson LE. Practice guideline for diagnosis and management of migraine headaches in children and adolescents: Part two. <i>J Pediatr Health Care</i>. 2008;22(1):52-59. doi:10.1016/j.pedhc.2007.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/18174091/pubmed" id="18174091" target="_blank">18174091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2366280">
<a name="2366280"></a>Gurwitz JH, Avorn J, Ross-Degnan D, et al. Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old. <i>JAMA</i>. 1990;264(4):471-475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2366280/pubmed" id="2366280" target="_blank">2366280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18541831">
<a name="18541831"></a>Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. <i>Arch Intern Med</i>. 2008;168(11):1219-1224. doi:10.1001/archinte.168.11.1219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/18541831/pubmed" id="18541831" target="_blank">18541831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9494149">
<a name="9494149"></a>Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs. <i>N Engl J Med</i>. 1998;338(11):727-734.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/9494149/pubmed" id="9494149" target="_blank">9494149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9605782">
<a name="9605782"></a>Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics. <i>Arch Intern Med</i>. 1998;158(10):1108-1112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/9605782/pubmed" id="9605782" target="_blank">9605782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15947398">
<a name="15947398"></a>Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. <i>BMJ</i>. 2005;330(7504):1366. doi:10.1136/bmj.330.7504.1366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15947398/pubmed" id="15947398" target="_blank">15947398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8422565">
<a name="8422565"></a>Hollingworth P. The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases. <i>Br J Rheumatol</i>. 1993;32(1):73-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/8422565/pubmed" id="8422565" target="_blank">8422565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18193919">
<a name="18193919"></a>Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. <i>Clin Pharmacokinet</i>. 2008;47(2):129-137. doi:10.2165/00003088-200847020-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/18193919/pubmed" id="18193919" target="_blank">18193919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2064481">
<a name="2064481"></a>Hoppmann RA, Peden JG, Ober SK. Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction. <i>Arch Intern Med</i>. 1991;151(7):1309-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2064481/pubmed" id="2064481" target="_blank">2064481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30317488">
<a name="30317488"></a>Horsley RD, Vogels ED, McField DAP, et al. Multimodal postoperative pain control is effective and reduces opioid use after laparoscopic Roux-en-Y gastric bypass. <i>Obes Surg</i>. 2019;29(2):394-400. doi:10.1007/s11695-018-3526-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/30317488/pubmed" id="30317488" target="_blank">30317488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2858695">
<a name="2858695"></a>Howard AM, Dowling J, Varigos G. Pseudoporphyria due to naproxen. <i>Lancet</i>. 1985;1(8432):819-820. doi:10.1016/s0140-6736(85)91478-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2858695/pubmed" id="2858695" target="_blank">2858695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15754275">
<a name="15754275"></a>Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. <i>Am J Kidney Dis</i>. 2005;45(3):531-539. doi:10.1053/j.ajkd.2004.12.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15754275/pubmed" id="15754275" target="_blank">15754275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11902253">
<a name="11902253"></a>Jacobi J, Fraser GL, Coursin DB, et al. Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult. <i>Crit Care Med</i>. 2002;30(1):119-141. http://www.sccm.org/pdf/sedatives.pdf
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11902253/pubmed" id="11902253" target="_blank">11902253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6653409">
<a name="6653409"></a>Jamali F, Stevens DR. Naproxen excretion in milk and its uptake by the infant. <i>Drug Intell Clin Pharm</i>. 1983;17(12):910-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/6653409/pubmed" id="6653409" target="_blank">6653409</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Jamali F, Tam YK, Stevens RD. Naproxen excretion in breast milk and its uptake by suckling infant. <i>Drug Intell Clin Pharm.</i> 1982;16(6):475.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18514729">
<a name="18514729"></a>Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. <i>Lancet</i>. 2008;371(9627):1854-1860. doi:10.1016/S0140-6736(08)60799-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/18514729/pubmed" id="18514729" target="_blank">18514729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1608854">
<a name="1608854"></a>Jick H, Derby LE, García Rodríguez LA, Jick SS, Dean AD. Liver disease associated with diclofenac, naproxen, and piroxicam. <i>Pharmacotherapy</i>. 1992;12(3):207-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/1608854/pubmed" id="1608854" target="_blank">1608854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaunitz.1">
<a name="Kaunitz.1"></a>Kaunitz AM. Abnormal uterine bleeding in nonpregnant reproductive-age patients: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2724096">
<a name="2724096"></a>Kean WF, Lock CJ, Rischke J, Butt R, Buchanan WW, Howard-Lock H. Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets. <i>J Pharm Sci</i>. 1989;78(4):324-327. doi:10.1002/jps.2600780413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2724096/pubmed" id="2724096" target="_blank">2724096</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. <i>Kidney Inter</i>. 2013;3(suppl):1-150.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24587953">
<a name="24587953"></a>Kim YJ, Lim KH, Kim MY, et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. <i>Allergy Asthma Immunol Res</i>. 2014;6(2):156-162. doi:10.4168/aair.2014.6.2.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/24587953/pubmed" id="24587953" target="_blank">24587953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31545385">
<a name="31545385"></a>Klar H, Sotošek N, Šelb J, Košnik M. Selective hypersensitivity to a single nonsteroidal anti-inflammatory drug. <i>Acta Dermatovenerol Alp Pannonica Adriat</i>. 2019;28(3):97-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/31545385/pubmed" id="31545385" target="_blank">31545385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15647052">
<a name="15647052"></a>Klote MM, Smith LJ. A case of anaphylaxis to naproxen. <i>Allergy</i>. 2005;60(2):260-261. doi:10.1111/j.1398-9995.2004.00630.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15647052/pubmed" id="15647052" target="_blank">15647052</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Knodel LC. Preventing NSAID-Induced Ulcers: The Role of Misoprostol. <i>Consult Pharm</i>. 1989;4:37-41.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17609236">
<a name="17609236"></a>Knowles SR, Drucker AM, Weber EA, Shear NH. Management options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivity. <i>Ann Pharmacother</i>. 2007;41(7):1191-1200. doi:10.1345/aph.1K023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/17609236/pubmed" id="17609236" target="_blank">17609236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24280110">
<a name="24280110"></a>Kohli P, Steg PG, Cannon CP, et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. <i>Am J Med</i>. 2014;127(1):53-60.e1. doi:10.1016/j.amjmed.2013.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/24280110/pubmed" id="24280110" target="_blank">24280110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27881247">
<a name="27881247"></a>Koncicki HM, Unruh M, Schell JO. Pain management in CKD: a guide for nephrology providers. <i>Am J Kidney Dis</i>. 2017;69(3):451-460. doi:10.1053/j.ajkd.2016.08.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/27881247/pubmed" id="27881247" target="_blank">27881247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21631520">
<a name="21631520"></a>Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. <i>Allergy</i>. 2011;66(7):818-829. doi:10.1111/j.1398-9995.2011.02557.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/21631520/pubmed" id="21631520" target="_blank">21631520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117484">
<a name="24117484"></a>Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. <i>Allergy</i>. 2013;68(10):1219-1232. doi:10.1111/all.12260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/24117484/pubmed" id="24117484" target="_blank">24117484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25749768">
<a name="25749768"></a>Kowalski ML, Makowska JS. Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice? <i>Allergy Asthma Immunol Res</i>. 2015;7(4):312-320. doi:10.4168/aair.2015.7.4.312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/25749768/pubmed" id="25749768" target="_blank">25749768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30216468">
<a name="30216468"></a>Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. <i>Allergy</i>. 2019;74(1):28-39. doi:10.1111/all.13599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/30216468/pubmed" id="30216468" target="_blank">30216468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12900801">
<a name="12900801"></a>Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. <i>Am J Kidney Dis</i>. 2003;42(2):217-228. doi:10.1016/s0272-6386(03)00645-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/12900801/pubmed" id="12900801" target="_blank">12900801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12014386">
<a name="12014386"></a>Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. <i>Eur J Pediatr</i>. 2002;161(4):202-207. doi:10.1007/s00431-002-0915-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/12014386/pubmed" id="12014386" target="_blank">12014386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28483309">
<a name="28483309"></a>Laidlaw TM, Cahill KN. Current knowledge and management of hypersensitivity to aspirin and NSAIDs. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):537-545. doi:10.1016/j.jaip.2016.10.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/28483309/pubmed" id="28483309" target="_blank">28483309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20955443">
<a name="20955443"></a>Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. <i>Aliment Pharmacol Ther</i>. 2010;32(10):1240-1248. doi:10.1111/j.1365-2036.2010.04465.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/20955443/pubmed" id="20955443" target="_blank">20955443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25402512">
<a name="25402512"></a>Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. <i>Ann Intern Med</i>. 2014;161(10):690-698. doi:10.7326/M13-1581<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/25402512/pubmed" id="25402512" target="_blank">25402512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8151484">
<a name="8151484"></a>Lang BA, Finlayson LA. Naproxen-Induced Pseudoporphyria in Patients With Juvenile Rheumatoid Arthritis. <i>J Pediatr</i>. 1994;124(4):639-642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/8151484/pubmed" id="8151484" target="_blank">8151484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7909103">
<a name="7909103"></a>Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. <i>Lancet</i>. 1994;343(8905):1075-1078. doi:10.1016/s0140-6736(94)90185-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/7909103/pubmed" id="7909103" target="_blank">7909103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23299844">
<a name="23299844"></a>Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ</i>. 2013;346:e8525. doi:10.1136/bmj.e8525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23299844/pubmed" id="23299844" target="_blank">23299844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30742315">
<a name="30742315"></a>Lethaby A, Wise MR, Weterings MA, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. <i>Cochrane Database Syst Rev</i>. 2019;2(2):CD000154. doi:10.1002/14651858.CD000154.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/30742315/pubmed" id="30742315" target="_blank">30742315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11735667">
<a name="11735667"></a>Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. <i>Paediatr Drugs</i>. 2001;3(11):817-858.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11735667/pubmed" id="11735667" target="_blank">11735667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2552870">
<a name="2552870"></a>Martinez R, Smith DW, Frankel LR. Severe Metabolic Acidosis After Acute Naproxen Sodium Ingestion. <i>Ann Emerg Med</i>. 1989;18(10):1102-1104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2552870/pubmed" id="2552870" target="_blank">2552870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21797863">
<a name="21797863"></a>McDonald SA, Hershey AD, Pearlman E, et al. Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents. <i>Headache</i>. 2011;51(9):1374-1387. doi:10.1111/j.1526-4610.2011.01965.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/21797863/pubmed" id="21797863" target="_blank">21797863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27816920">
<a name="27816920"></a>McInerney KA, Hatch EE, Wesselink AK, Rothman KJ, Mikkelsen EM, Wise LA. Preconception use of pain-relievers and time-to-pregnancy: a prospective cohort study. <i>Hum Reprod</i>. 2017;32(1):103-111. doi:10.1093/humrep/dew272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/27816920/pubmed" id="27816920" target="_blank">27816920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31416889">
<a name="31416889"></a>Mérida E, Praga M. NSAIDs and nephrotic syndrome. <i>Clin J Am Soc Nephrol</i>. 2019;14(9):1280-1282. doi:10.2215/CJN.08090719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/31416889/pubmed" id="31416889" target="_blank">31416889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23360563">
<a name="23360563"></a>Misurac JM, Knoderer CA, Leiser JD, Nailescu C, Wilson AC, Andreoli SP. Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children. <i>J Pediatr</i>. 2013;162(6):1153-1159.e1. doi:10.1016/j.jpeds.2012.11.069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23360563/pubmed" id="23360563" target="_blank">23360563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10879670">
<a name="10879670"></a>Mohammed EP, Stevens JM. Recurrence of arthrotec-associated nephrotic syndrome with re-challenge. <i>Clin Nephrol</i>. 2000;53(6):483-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/10879670/pubmed" id="10879670" target="_blank">10879670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11078175">
<a name="11078175"></a>Morgan TO, Anderson A, Bertram D. Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril. <i>Am J Hypertens</i>. 2000;13(11):1161-1167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11078175/pubmed" id="11078175" target="_blank">11078175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6822116">
<a name="6822116"></a>Nader DA, Schillaci RF. Pulmonary Infiltrates With Eosinophilia Due to Naproxen. <i>Chest</i>. 1983;83(2):280-282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/6822116/pubmed" id="6822116" target="_blank">6822116</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Naprelan controlled release tablets (naproxen) [prescribing information]. Morristown, NJ: Almatica Pharma Inc; April 2021.</div>
</li>
<li>
<div class="reference">
                  Naprosyn (naproxen) [product monograph]: Brantford, Ontario, Canada: Methapharm Inc; January 2022.</div>
</li>
<li>
<div class="reference">
                  Naprosyn (naproxen) oral suspension [prescribing information]. Athens, GA: Athena Bioscience, LLC; April 2021.</div>
</li>
<li>
<div class="reference">
                  Naprosyn tablet (naproxen) [prescribing information]. Mississauga, Ontario: Hoffman-La Roche Limited; October 2014.</div>
</li>
<li>
<div class="reference">
                  Naproxen tablets [prescribing information]. East Windsor, NJ: Aurobindo Pharma; May 2021.</div>
</li>
<li>
<div class="reference">
                  Naproxen tablets [product monograph]. Laval, Quebec, Canada: Pro Doc Ltee; April 2022.</div>
</li>
<li>
<div class="reference">
                  Naproxen sodium tablets [prescribing information]. East Windsor, NJ: Aurobindo Pharma; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31264694">
<a name="31264694"></a>Nash DM, Markle-Reid M, Brimble KS, et al. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study. <i>Nephrol Dial Transplant</i>. 2019;34(7):1145-1154. doi:10.1093/ndt/gfz062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/31264694/pubmed" id="31264694" target="_blank">31264694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31264694">
<a name="31264694"></a>National Institute of Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline 183. Published September 3, 2014. https://www.nice.org.uk/guidance/cg183. Accessed October 29, 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/31264694/pubmed" id="31264694" target="_blank">31264694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3893730">
<a name="3893730"></a>Nestvold K, Kloster R, Partinen M, Sulkava R. Treatment of acute migraine attack: naproxen and placebo compared. <i>Cephalgia</i>. 1985;5(2):115-119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/3893730/pubmed" id="3893730" target="_blank">3893730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10687453">
<a name="10687453"></a>Nguyen AM, Graham DY, Gage T, et al. Nonsteroidal Anti-inflammatory Drug Use in Dentistry: Gastrointestinal Implications. <i>Gen Dent</i>. 1999;47(6):590-596.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/10687453/pubmed" id="10687453" target="_blank">10687453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27959716">
<a name="27959716"></a>Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. <i>N Engl J Med</i>. 2016;375(26):2519-2529. doi:10.1056/NEJMoa1611593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/27959716/pubmed" id="27959716" target="_blank">27959716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3045551">
<a name="3045551"></a>Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (2). <i>N Engl J Med</i>. 1988;319(12):761-767. doi:10.1056/NEJM198809223191206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/3045551/pubmed" id="3045551" target="_blank">3045551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23633310">
<a name="23633310"></a>Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. <i>Cochrane Database Syst Rev</i>. 2013;(4):CD003481. doi:10.1002/14651858.CD003481.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23633310/pubmed" id="23633310" target="_blank">23633310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35233989">
<a name="35233989"></a>Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: recommendations for nonpharmacologic therapies, medication monitoring, immunizations, and imaging. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(4):505-520. doi:10.1002/acr.24839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/35233989/pubmed" id="35233989" target="_blank">35233989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28052268">
<a name="28052268"></a>Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. <i>Digestion</i>. 2017;95(1):22-28. doi:10.1159/000452356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/28052268/pubmed" id="28052268" target="_blank">28052268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10737277">
<a name="10737277"></a>Page J, Henry D. Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem. <i>Arch Intern Med</i>. 2000;160(6):777-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/10737277/pubmed" id="10737277" target="_blank">10737277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16469671">
<a name="16469671"></a>Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of <i>Helicobacter pylori</i> and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. <i>Clin Gastroenterol Hepatol</i>. 2006;4(2):130-142. doi:10.1016/j.cgh.2005.10.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/16469671/pubmed" id="16469671" target="_blank">16469671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pediapharm.1">
<a name="Pediapharm.1"></a>Pediapharm Naproxen Suspension (naproxen) [product monograph]. Bolton, Ontario, Canada: Medexus Inc; December 2022.</div>
</li>
<li>
<div class="reference">
                  Perez-Ruiz F. Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2012355">
<a name="2012355"></a>Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. <i>Ann Intern Med</i>. 1991;114(9):735-740. doi:10.7326/0003-4819-114-9-735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2012355/pubmed" id="2012355" target="_blank">2012355</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  pms-Naproxen (naproxen) [prescribing information]. Montreal, Quebec, Canada: Pharmascience Inc; June 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8435027">
<a name="8435027"></a>Pope JE, Anderson JJ, Felson DT. A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure. <i>Arch Intern Med</i>. 1993;153(4):477-484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/8435027/pubmed" id="8435027" target="_blank">8435027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2642448">
<a name="2642448"></a>Pounder R. Silent Peptic Ulceration: Deadly Silence or Golden Silence? <i>Gastroenterology</i>. 1989;96(2, pt 2)(suppl):626-631.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2642448/pubmed" id="2642448" target="_blank">2642448</a>]</span>
</div>
</li>
<li>
<div class="reference">
<i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 6th ed. American Pain Society; 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25439535">
<a name="25439535"></a>Rahman S, Malcoun A. Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and the kidneys. <i>Prim Care</i>. 2014;41(4):803-821. doi:10.1016/j.pop.2014.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/25439535/pubmed" id="25439535" target="_blank">25439535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20031832">
<a name="20031832"></a>Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. <i>Circ Cardiovasc Qual Outcomes</i>. 2009;2(3):155-163. doi:10.1161/CIRCOUTCOMES.108.805689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/20031832/pubmed" id="20031832" target="_blank">20031832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/27457514/pubmed" id="27457514" target="_blank">27457514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31021516">
<a name="31021516"></a>Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. <i>Arthritis Care Res (Hoboken)</i>. 2019;71(6):717-734. doi:10.1002/acr.23870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/31021516/pubmed" id="31021516" target="_blank">31021516</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Roddy E, Clarkson K, Blagojevic-Bucknall M, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. <i>Ann Rheum Dis</i>. 2020;79(2):276-284. doi:10.1136/annrheumdis-2019-216154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/31666237/pubmed" id="31666237" target="_blank">31666237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15692986">
<a name="15692986"></a>Ruperto N, Nikishina I, Pachanov ED, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. <i>Arthritis Rheum</i>. 2005;52(2):563-572. doi:10.1002/art.20860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15692986/pubmed" id="15692986" target="_blank">15692986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29020251">
<a name="29020251"></a>Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. <i>Eur Heart J</i>. 2017;38(44):3282-3292. doi:10.1093/eurheartj/ehx508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/29020251/pubmed" id="29020251" target="_blank">29020251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6110836">
<a name="6110836"></a>Rybo G, Nilsson S, Sikström B, Nygren KG. Naproxen in menorrhagia. <i>Lancet</i>. 1981;1(8220, pt 1):608-609. doi:10.1016/s0140-6736(81)92051-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/6110836/pubmed" id="6110836" target="_blank">6110836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33100559">
<a name="33100559"></a>Sahu N, Roy J, Vunnam R, Golamari R, Jain R. Naproxen-induced thrombocytopenia. <i>Proc (Bayl Univ Med Cent)</i>. 2020;33(4):653-654. doi:10.1080/08998280.2020.1798724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/33100559/pubmed" id="33100559" target="_blank">33100559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3545733">
<a name="3545733"></a>Sanford-Driscoll M, Knodel LC. Induction of hemolytic anemia by nonsteroidal antiinflammatory drugs. <i>Drug Intell Clin Pharm</i>. 1986;20(12):925-934. doi:10.1177/106002808602001202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/3545733/pubmed" id="3545733" target="_blank">3545733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sasi.2020">
<a name="Sasi.2020"></a>Sasi S, Altarawneh H, Petkar MA, Nair AP. Drug reaction with eosinophilia and systemic symptoms secondary to naproxen: a case report and literature review. <i>Case Rep Acute Med</i>. 2020;3:63–72. doi:10.1159/000509712</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11668110">
<a name="11668110"></a>Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. <i>Arch Dis Child</i>. 2001;85(5):421-426. doi:10.1136/adc.85.5.421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11668110/pubmed" id="11668110" target="_blank">11668110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19269020">
<a name="19269020"></a>Schjerning O, Larsen TB, Damkier P. The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. <i>Thromb Res</i>. 2009;124(2):208-212. doi:10.1016/j.thromres.2009.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/19269020/pubmed" id="19269020" target="_blank">19269020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21555710">
<a name="21555710"></a>Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. <i>Circulation</i>. 2011;123(20):2226-2235. doi:10.1161/CIRCULATIONAHA.110.004671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/21555710/pubmed" id="21555710" target="_blank">21555710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25710657">
<a name="25710657"></a>Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. <i>JAMA</i>. 2015;313(8):805-814. doi:10.1001/jama.2015.0809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/25710657/pubmed" id="25710657" target="_blank">25710657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17005625">
<a name="17005625"></a>Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. <i>Am J Epidemiol</i>. 2006;164(9):881-889. doi:10.1093/aje/kwj331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/17005625/pubmed" id="17005625" target="_blank">17005625</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Schwedt TJ, Garza Ivan. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 12, 2021.</div>
</li>
<li>
<div class="reference">
                  Schwenk ES. Nonopioid pharmacotherapy for acute pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7306246">
<a name="7306246"></a>Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. <i>Arthritis Rheum</i>. 1981;24(9):1208-1210. doi:10.1002/art.1780240917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/7306246/pubmed" id="7306246" target="_blank">7306246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7640588">
<a name="7640588"></a>Shaunak S, Brown P, Morgan-Hughes JA. Exacerbation of Idiopathic Parkinson's Disease by Naproxen. <i>BMJ</i>, 1995;311(7002):422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/7640588/pubmed" id="7640588" target="_blank">7640588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33632948">
<a name="33632948"></a>Shi CL, Zhang Y, Zhang ZY, Zhou J, Tang XM. Comparative efficacy and safety of non-steroidal anti-inflammatory drugs in patients with juvenile idiopathic arthritis: a systematic review and network meta-analysis. <i>Indian Pediatr</i>. 2021;58(2):162-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/33632948/pubmed" id="33632948" target="_blank">33632948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10993991">
<a name="10993991"></a>Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [published correction appears in <i>Neurology</i>. 2000;56(1):142]. <i>Neurology</i>. 2000;55(6):754-762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/10993991/pubmed" id="10993991" target="_blank">10993991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11925405">
<a name="11925405"></a>Siu SS, Yeung JH, Lau TK. An in-vivo study on placental transfer of naproxen in early human pregnancy. <i>Hum Reprod</i>. 2002;17(4):1056-1059. doi:10.1093/humrep/17.4.1056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11925405/pubmed" id="11925405" target="_blank">11925405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23868909">
<a name="23868909"></a>Sivera F, Andrés M, Carmona L, et al. Multinational Evidence-Based Recommendations for the Diagnosis and Management of Gout: Integrating Systematic Literature Review and Expert Opinion of a Broad Panel of Rheumatologists in the 3e Initiative. <i>Ann Rheum Dis</i>. 2014;73(2):328-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23868909/pubmed" id="23868909" target="_blank">23868909</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Smith RP, Kaunitz AM. Dysmenorrhea in adult women: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 1, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12435222">
<a name="12435222"></a>Snow V, Weiss K, Wall EM, et al. Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache. <i>Ann Intern Med</i>. 2002;137(10):840-849.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/12435222/pubmed" id="12435222" target="_blank">12435222</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Solomon DH. NSAIDs: therapeutic use and variability of response in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28756267">
<a name="28756267"></a>Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. <i>Am J Med</i>. 2017;130(12):1415-1422.e4. doi:10.1016/j.amjmed.2017.06.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/28756267/pubmed" id="28756267" target="_blank">28756267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15837266">
<a name="15837266"></a>Steinhubl SR. The Use of Anti-Inflammatory Analgesics in the Patient With Cardiovascular Disease: What a Pain. <i>J Am Coll Cardiol</i>. 2005.45(8):1302-1303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/15837266/pubmed" id="15837266" target="_blank">15837266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11709613">
<a name="11709613"></a>Stéphan JL, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. <i>Rheumatology (Oxford)</i>. 2001;40(11):1285-1292. doi:10.1093/rheumatology/40.11.1285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/11709613/pubmed" id="11709613" target="_blank">11709613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8379803">
<a name="8379803"></a>Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M, Lundin FE Jr. Nonsteroidal anti-inflammatory drugs and neutropenia. <i>Arch Intern Med</i>. 1993;153(18):2119-2124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/8379803/pubmed" id="8379803" target="_blank">8379803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31937550">
<a name="31937550"></a>Szeto CC, Sugano K, Wang JG, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. <i>Gut</i>. 2020;69(4):617-629. doi:10.1136/gutjnl-2019-319300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/31937550/pubmed" id="31937550" target="_blank">31937550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26943657">
<a name="26943657"></a>Thorell A, MacCormick AD, Awad S, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. <i>World J Surg</i>. 2016;40(9):2065-2083. doi:10.1007/s00268-016-3492-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/26943657/pubmed" id="26943657" target="_blank">26943657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21224324">
<a name="21224324"></a>Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. <i>BMJ</i>. 2011;342:c7086. doi:10.1136/bmj.c7086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/21224324/pubmed" id="21224324" target="_blank">21224324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic</a>. Published October 15, 2020. Accessed October 20, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>. Published July 9, 2015. Accessed October 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17410098">
<a name="17410098"></a>Vadivel N, Trikudanathan S, Singh AK. Analgesic nephropathy. <i>Kidney Int</i>. 2007;72(4):517-520. doi:10.1038/sj.ki.5002251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/17410098/pubmed" id="17410098" target="_blank">17410098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10974130">
<a name="10974130"></a>Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. <i>N Engl J Med</i>. 2000;343(10):674-681. doi:10.1056/NEJM200009073431001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/10974130/pubmed" id="10974130" target="_blank">10974130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2199127">
<a name="2199127"></a>Verbeeck RK. Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs. <i>Clin Pharmacokinet.</i> 1990;19(1):44-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2199127/pubmed" id="2199127" target="_blank">2199127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7443602">
<a name="7443602"></a>Victorino RM, Silveira JC, Baptista A, de Moura MC. Jaundice associated with naproxen. <i>Postgrad Med J</i>. 1980;56(655):368-370. doi:10.1136/pgmj.56.655.368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/7443602/pubmed" id="7443602" target="_blank">7443602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1321554">
<a name="1321554"></a>Villanueva M, Heckenberger R, Palmér M, Schrör K. Stereospecific and non-stereospecific effects of ibuprofen on human platelet and polymorphonuclear leukocyte functions. <i>Agents Actions Suppl</i>. 1992;37:162-170. doi:10.1007/978-3-0348-7262-1_22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/1321554/pubmed" id="1321554" target="_blank">1321554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7965441">
<a name="7965441"></a>Wallace CA, Farrow D, Sherry DD. Increased risk of facial scars in children taking nonsteroidal antiinflammatory drugs. <i>J Pediatr</i>. 1994;125(5 Pt 1):819-822. doi:10.1016/s0022-3476(94)70084-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/7965441/pubmed" id="7965441" target="_blank">7965441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20101062">
<a name="20101062"></a>Ward KE, Archambault R, Mersfelder TL. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature. <i>Am J Health Syst Pharm</i>. 2010;67(3):206-213. doi:10.2146/ajhp080603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/20101062/pubmed" id="20101062" target="_blank">20101062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10377455">
<a name="10377455"></a>Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. <i>Proc Natl Acad Sci U S A</i>. 1999;96(13):7563-7568. doi:10.1073/pnas.96.13.7563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/10377455/pubmed" id="10377455" target="_blank">10377455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12020179">
<a name="12020179"></a>Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. <i>Arch Intern Med</i>. 2002;162(10):1105-1110. doi:10.1001/archinte.162.10.1105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/12020179/pubmed" id="12020179" target="_blank">12020179</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Weiss PF. Oligoarticular juvenile idiopathic arthritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32488260">
<a name="32488260"></a>Wesselink AK, Bresnick KA, Hatch EE, et al. Association between male use of pain medication and fecundability. <i>Am J Epidemiol</i>. 2020;189(11):1348-1359. doi:10.1093/aje/kwaa096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/32488260/pubmed" id="32488260" target="_blank">32488260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2183665">
<a name="2183665"></a>Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. <i>Ann Intern Med</i>. 1990;112(8):568-576. doi:10.7326/0003-4819-112-8-568<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/2183665/pubmed" id="2183665" target="_blank">2183665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10390124">
<a name="10390124"></a>Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. <i>Am J Med</i>. 1999;106(5B):13S-24S. doi:10.1016/s0002-9343(99)00113-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/10390124/pubmed" id="10390124" target="_blank">10390124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30207919">
<a name="30207919"></a>White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. <i>N Engl J Med</i>. 2018;379(11):1060-1070. doi:10.1056/NEJMra1712125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/30207919/pubmed" id="30207919" target="_blank">30207919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25881677">
<a name="25881677"></a>Winner P, Linder S, Hershey AD. Consistency of response to sumatriptan/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescence. <i>Headache</i>. 2015;55(4):519-528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/25881677/pubmed" id="25881677" target="_blank">25881677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23968886">
<a name="23968886"></a>Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society guideline: acute drug therapy for migraine headache. <i>Can J Neurol Sci</i>. 2013;40(5)(suppl 3):S1-S80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23968886/pubmed" id="23968886" target="_blank">23968886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23741058">
<a name="23741058"></a>Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327. doi:10.1161/CIR.0b013e31829e8776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/23741058/pubmed" id="23741058" target="_blank">23741058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29667211">
<a name="29667211"></a>Yeomans ND, Graham DY, Husni ME, et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. <i>Aliment Pharmacol Ther</i>. 2018;47(11):1453-1463. doi:10.1111/apt.14610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/29667211/pubmed" id="29667211" target="_blank">29667211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9494148">
<a name="9494148"></a>Yeomans ND, Tulassay Z, Juhasz L, et al. A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs. <i>N Engl J Med</i>. 1998;338(11):719-726.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/9494148/pubmed" id="9494148" target="_blank">9494148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3523328">
<a name="3523328"></a>Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. <i>Obstet Gynecol</i>. 1986;68(1):10-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/3523328/pubmed" id="3523328" target="_blank">3523328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zeltzer.2020">
<a name="Zeltzer.2020"></a>Zeltzer LK, Krane EJ, Levy RL. Pediatric pain management. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 76.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32317121">
<a name="32317121"></a>Zhan M, Doerfler RM, Xie D, et al. Association of opioids and nonsteroidal anti-inflammatory drugs with outcomes in CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) Study. <i>Am J Kidney Dis</i>. 2020;76(2):184-193. doi:10.1053/j.ajkd.2019.12.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/32317121/pubmed" id="32317121" target="_blank">32317121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16707532">
<a name="16707532"></a>Zhang W, Doherty M, Bardin T, et al. EULAR Evidence Based Recommendations for Gout. Part II: Management. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Ann Rheum Dis</i>. 2006;65(10):1312-1324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/16707532/pubmed" id="16707532" target="_blank">16707532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-447795">
<a name="447795"></a>Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. <i>J Clin Endocrinol Metab</i>. 1979;48(6):895-900. doi:10.1210/jcem-48-6-895<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naproxen-drug-information/abstract-text/447795/pubmed" id="447795" target="_blank">447795</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9682 Version 908.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
